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CHAPTER ONE
INTRODUCTION

Heart Failure (HF) is one of the leading causes of morbidity and mortality
in the human population and represents a common endpoint for several diseases
including

inherited

cardiomyopathies

(Niimura,

Bachinski

et

al.

1998).

Hypertrophic Cardiomyopathy (HCM) is characterized by left ventricular wall
thickening, diastolic dysfunction, and sarcomere disarray (Watkins, MacRae et al.
1993, Maron, Gardin et al. 1995, Watkins, Conner et al. 1995, Spirito, Seidman
et al. 1997). Mutations in sarcomeric protein encoding genes have been linked to
HCM although the mechanisms by which these mutations act remain unclear.
Therefore, functional characterization of frequent mutations would help define the
mechanisms of pathogenesis and provide novel therapeutic targets.
The gene MYBPC3, encoding cardiac myosin binding protein-C (cMyBPC), has been established as the second most commonly mutated gene in HCM
cases. As a majority of these mutations have been determined to result in a null
allele which does not produce any protein, it has been suggested that
haploinsufficiency (i.e. the inability for one allele to express enough protein) of
the MYBPC3 gene is responsible for the development of HCM (Bonne, Carrier et
al. 1995, Watkins, Conner et al. 1995). In symptomatic heterozygous patients

1

2
with null MYBPC3 mutations, reduced cMyBP-C levels have been shown (van
Dijk, Dooijes et al. 2009). However, as protein levels in asymptomatic carriers
have not been assessed, it is unclear if reduced protein is causative for or occurs
as a result of the onset of HCM. Therefore, in this work I tested whether
heterozygous (Het) mice carrying a knock-in C’ truncation mutation that
expresses normal levels of cMyBP-C had alterations in function, and whether
stress-induced hypertrophy resulted in decreased levels of cMyBP-C.
The results of this study show that Het mice have dysfunction under
normal conditions and show significantly reduced MYBPC3 expression in Het
hearts with preserved cMyBP-C levels. Significant impairments were observed in
cardiomyocyte force generation and whole-organ diastolic function in naïve Het
mice compared to WT controls. Following transverse aortic constriction (TAC)
pressure-overload cardiac stress Het mice show significantly greater hypertrophy
and reduced cMyBP-C levels compared to WT controls. Force generation is
reduced both in TAC and sham Het cardiomyocytes and significant Ca2+
sensitization is also observed. Finally, significant deficits in systolic function in
vivo are evident in the Het TAC hearts compared to WT TAC.
These findings demonstrate that Het MYBPC3 truncation mutant mice
have baseline dysfunction that leads to exacerbated development of hypertrophy
and dysfunction following stress. These results suggest that human carriers may
have functional deficits prior to the onset of remodeling and are predisposed to
developing exacerbated hypertrophy with worsened cardiac function.

CHAPTER TWO
LITERATURE REVIEW

2.1 Cardiovascular Physiology in Health and Disease
Hypertrophic cardiomyopathy (HCM) is a genetically based pathological
enlargement of the heart that occurs in the human population with a frequency of
1 in 500 individuals and can result in the development of heart failure (HF)
(Watkins, MacRae et al. 1993, Bonne, Carrier et al. 1995, Watkins, Conner et al.
1995, Niimura, Bachinski et al. 1998). HF is clinically defined as the inability of
the heart to pump a sufficient amount of blood to meet the needs of the body. HF
is also a common end-point for a variety of cardiovascular diseases; it is
estimated to affect approximately eighty million adults per year in the United
States and is one of the leading causes of death in the human population (Go,
Mozaffarian et al. 2013).
HCM has been described as a disease of the cardiac sarcomere, as
mutations in genes encoding sarcomeric proteins have been identified as
causative in the majority of HCM cases (Arad, Seidman et al. 2002). Cardiac
myosin binding protein-C (cMyBP-C) is a sarcomeric trans-filament protein that is
involved in the regulation of sarcomere structure and function. Mutations in the
3
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cMyBP-C gene (MYBPC3) are associated with ~34% of all cardiomyopathy
cases, of which 70% are predicted to produce C’-truncated proteins (Spirito,
Seidman et al. 1997, Morita, Rehm et al. 2008). Strikingly, one specific MYBPC3
mutation has been estimated to occur in over 60 million people worldwide,
underscoring the necessity of determining its mechanism in the pathogenesis of
HF (Dhandapany, Sadayappan et al. 2009).
MYBPC3 mutations are associated with incomplete disease penetrance
and/or late disease onset and are highly associated with HF (Niimura, Bachinski
et al. 1998, Moolman, Reith et al. 2000, Dhandapany, Sadayappan et al. 2009).
The functional and pathological consequences of MYBPC3 mutations are not
fully characterized, as the majority of these mutations are expected to generate
C’-truncated cMyBP-C that is often not found in cardiac tissue from affected HCM
patients (Moolman, Reith et al. 2000, Marston, Copeland et al. 2009, van Dijk,
Dooijes et al. 2009). This indicates that the truncated protein is either not
expressed or is rapidly degraded. Furthermore, in symptomatic human patients
carrying truncating MYBPC3 mutations, cMyBP-C levels have been shown to be
decreased (van Dijk, Dooijes et al. 2009). These observations suggest that the
development of HCM could be caused by insufficient cMyBP-C production due to
haploinsufficiency of the MYBPC3 gene, meaning that a single functional copy of
the gene is insufficient to achieve a wild-type (WT) phenotype. However, reduced
cMyBP-C levels have not been established to be causative for, or as a result of
the development of HCM in human carriers.
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2.1.1 The Healthy and Sick Heart
The pump function of the heart supplies the human body with oxygen and
nutrients through the circulation of blood. Normal cardiac function requires
dynamic regulation in order provide proper blood supply in response to the
changing needs of the body. The contraction and relaxation of the heart is
achieved through an exquisitely tuned molecular machine and disruption of any
of the constitutive parts can result in aberrant function and development of
disease. Perturbations in cardiac function can develop into life threatening
situations which must be addressed immediately in order to restore proper organ
function and preserve the life of the individual. Due to the essential role of the
heart and its complexity, cardiovascular disease is the leading cause of death in
the human population, accounting for approximately 1 in 3 deaths (Go,
Mozaffarian et al. 2013).
Cardiovascular disease can occur for a host of reasons, with each distinct
pathological situation presenting different challenges for effective treatment.
HCM is a general term for pathological enlargement of the heart that occurs in
the absence of an externally identifiable cause. This distinction differentiates
HCM from other diseases that cause hypertrophy, such as chronic high blood
pressure, diabetes, or autoimmune disease (Maron, Gardin et al. 1995). Due to
this clinical definition, HCM is diagnosed by excluding other causes of
hypertrophy, and it wasn’t until the mid-1990’s that a genetic cause for the
disease was defined (Watkins, MacRae et al. 1993, Bonne, Carrier et al. 1995).
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Originally, this form of HCM was termed Familial Hypertrophic Cardiomyopathy,
as it followed Mendelian inheritance patterns and persisted in families (Bonne,
Carrier et al. 1995).
Populations with ancient founder mutations typically have a high
prevalence of these mutations. In the human population as a whole, the
prevalence of HCM is 1 case in every 500 people, making it one of the more
common forms of heart disease (Go, Mozaffarian et al. 2013). The discoveries
that defined the genetic cause of HCM established the general understanding
that HCM is a disease of the sarcomere (Bonne, Carrier et al. 1995, Watkins,
Conner et al. 1995). Furthermore, HCM typically results in a gradual decline of
cardiac function towards HF, which in some cases can include a transition to
dilated cardiomyopathy (DCM). HF is a common end point for a variety of
cardiovascular diseases including HCM, DCM, myocardial ischemia and
infarction, and is estimated to affect over 5 million Americans over 20 years of
age (Go, Mozaffarian et al. 2013). However, in order to understand the
pathological development of HCM, it is important to understand how specific
mutations affect sarcomere function and how these changes perturb total
cardiovascular physiology.

2.1.2 Cardiac Anatomy and Function
The role of the heart is to circulate blood to supply the body’s tissues with
oxygen and nutrients and to transport waste products for removal. In order to
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accomplish this task, the heart functions as a unidirectional pump that
pressurizes blood in order to perfuse the body. The pump function of the heart
can be explained by examining the anatomy of the organ.
The mammalian heart is made up of four chambers, two atria and two
ventricles, attached to the systemic venous and arterial systems. Blood enters
the right atrium from the venous system via the vena cava. During cardiac
relaxation, known as diastole, blood passively flows through the right atrium into
the right ventricle due to the slightly higher blood pressure in the venous system
than in the diastolic right atrium and ventricle. During atrial systole, the right
atrium contracts to assist in right ventricular filling. When the right ventricle is full
and begins to contract, the tricuspid valve separating the right atrium and
ventricle closes due to the higher pressure in the contracting ventricle. The right
ventricle contracts until the blood inside has been sufficiently pressurized to open
the pulmonary valve (typically around 25mmHg) that separates the right ventricle
from the pulmonary artery. Blood is then ejected into the pulmonary circulation
where gas exchange occurs in the alveolar capillaries. Following contraction the
pressure in the right ventricle drops below the pressure in the pulmonary artery,
causing blood to flow backwards; however, this backwards flow is prevented by
the closing of the pulmonary semilunar valve that separates the right ventricle
from the pulmonary artery.
The left side of the heart mirrors what occurs on the right, except the
pressures exerted are much higher. Oxygenated blood returns from the lungs via
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the pulmonary vein and empties into the left atrium and passively fills the left
ventricle during diastole. Passive left ventricular filling slows as the ventricle fills
with more blood due to the elastic properties of the left ventricle. During atrial
systole the contraction of the left atrium ejects an additional amount of blood into
the left ventricle, which in a healthy heart amounts to approximately 5% of total
left ventricle peak diastolic volume. This relationship can be defined by the early
to atrial ratio (E/A ratio) of LV filling (Figure 1). An additional parameter of
diastolic function is the early E’ and atrial A’ (recoil) of the heart, measured as the
movement of the tissue surrounding the mitral valve. This relationship can also
be expressed as a ratio of E’/A’ (Nagueh, Appleton et al. 2009).
After filling the left ventricle contracts causing increased blood pressure
that closes the mitral (or bicuspid) valve, which separates the left atrium from the
ventricle. This prevents backwards flow of blood during ventricular systole.
Isovolumic left ventricular contraction occurs until the blood reaches sufficient
pressure to open the aortic valve, which is a pressure equal to diastolic blood
pressure (typically around 80mmHg in a healthy adult). Blood rapidly ejects into
the aorta and peripheral arteries until the end of ventricular systole, at which
point the left ventricle begins to relax. High systemic blood pressure forces the
aortic valve to close when pressure inside the left ventricle drops following
contraction, preventing retrograde flow. During a typical heart beat the human left
ventricle will eject 65-75% of the total LV volume, a value known as ejection
fraction (Kass, Yamazaki et al. 1986).
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The heart pumps blood to circulate oxygen and nutrients to the peripheral
tissues. However, the heart must also perfuse itself, as the blood within the atria
and ventricles is not useable by the cardiac tissue. To this end coronary arteries
branch off of the aorta immediately superior to the aortic valve. These arteries
branch several times, providing oxygenated blood to the whole heart. Occlusions
in these arteries from plaque deposits or thrombosis can lead to ischemia
localized downstream of the blockage. If perfusion is not restored by clotdissolving drugs or angioplasty then the ischemic area will become necrotic,
resulting in a myocardial infarction (Go, Mozaffarian et al. 2013).
Hypertrophic remodeling alters the anatomy of the heart. As the left
ventricle enlarges the internal diameter of the ventricle gets smaller, reducing the
amount of blood that can fill the ventricle in diastole. As the myocardium thickens
in hypertrophy, it also becomes stiffer, which causes additional resistance to
diastolic filling. A hallmark of this diastolic dysfunction is observed in the E/A
ratio, where early filling becomes a smaller component of total diastolic filling,
and the atrial component becomes more important. When this occurs the E/A
ratio decreases (Figure 1) (Nagueh, Appleton et al. 2009).
Cardiac systolic function is typically compensated in early hypertrophy,
with normal ejection fraction and maintained cardiac output. However, if cardiac
function begins to decompensate, congestive heart failure can develop, with
blood pooling in the pulmonary and venous circulation, typically resulting in distal
edema (Go, Mozaffarian et al. 2013). At this stage the E/A ratio can be altered in
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a variety of ways, however one potential observation is a merged E and A peak,
when the pressure in the pulmonary circulation increases enough that the
opening of the mitral valve is followed by one large influx of blood to the LV,
instead of two distinct filling phases (Nagueh, Appleton et al. 2009).
As diastolic function can be an early indication of cardiac dysfunction,
prior to other overt manifestations, in this study the E/A, and E’/A’ parameters
were measured to assess functional decline in naïve heterozygous mice as well
as mice developing pressure-overload induced hypertrophy.
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Figure 1. Schematized Depiction of the E/A Ratio.
The early (E) and atrial (A) diastolic filling peaks are represented above in a
typically normal ratio (left) and in a situation where the ratio is decreased (right).
The deflections below the 0 blood flow velocity line represent aortic ejection
velocity, with the periods between the diastolic filling and aortic eject representing
the isovolumic filling and isovolumic ejection.
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2.1.3 The Pressure-Volume Relationship of the Left Ventricle
Understanding the anatomy of the heart provides an understanding of its
function; however, cardiac function in terms of the contraction and relaxation of
the ventricles can be better described using the four phases of the pressurevolume relationship (Figure 2A) (Suga and Sagawa 1974, Sagawa 1981, Kass,
Yamazaki et al. 1986).
During ventricular diastole the left ventricle passively fills with blood,
causing the volume to increase, but due to the compliance of the ventricle the
pressure only increases at the end of diastolic filling (phase I). Pressure will start
to rise if the heart is filled to the point where the compliance drops and the elastic
elements start to resist additional filling. The pressure exerted by the total
amount of blood filling the ventricle at the end of diastole is considered the preload on the heart. At the start of systole, the ventricle begins to contract, which
closes the mitral valve (point A) and seals the ventricular chamber. As the aortic
valve is also closed, the volume within the ventricle remains constant, with
increasing pressure as the heart exerts force on the blood. This phase is termed
isovolumic contraction (phase II).
The ventricle exerts force on the preload until the pressure in the LV is
greater than the diastolic blood pressure on the distal side of the aortic valve, at
which point the aortic valve opens (point B) and the rapid ejection phase begins
(phase III). The level of diastolic blood pressure the heart is pumping against is
considered the afterload. The heart continues to eject blood until the ventricle
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stops contracting, after which the ventricular pressure begins to fall. Once the
pressure in the heart falls below the systolic blood pressure, the aortic valve
closes (point C) which marks the end of systole. The left ventricle then relaxes,
with pressures still high enough to keep the mitral valve closed, meaning this
phase has no change in volume, with a rapid decline in pressure and is termed
isovolumic relaxation (phase IV). Once pressure in the left ventricle falls below
the pressure in the left atrium, the mitral valve opens (point D) and again allows
filling of the ventricle and the cardiac cycle repeats.
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Figure 2. The Cardiac Pressure-Volume Relationship.
A. Schematized depiction of the pressure-volume relationship for left ventricular
function. Letters denote closing or opening of valves (A: mitral valve closes; B:
aortic valve opens; C: aortic valve closes; D: mitral valve opens) and numerals
identify stages of the cardiac cycle (I: ventricular filling; II: isovolumic contraction;
III: ventricular ejection; IV: isovolumic relaxation). B. Diagram of a normal loop
(black) compared to a loop from a heart pumping against a high afterload (grey)
and a failing heart in dilation (red). C. Diagram depicting the ESPVR and EDPVR
during a reduction in cardiac pre-load.
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During hypertension or aortic stenosis the heart is required to work harder
to open the aortic valve and eject blood (Figure 2B). Following prolonged
periods of increased work the heart will begin to hypertrophy which can result in
the eventual death of cardiomyocytes, replacement with fibroblasts, potential
thinning of the ventricle wall and the development of heart failure (Gonzalez,
Fortuno et al. 2003). In cases where the ventricular walls thin and the heart
dilates, the LV enlarges and the total ventricular volume in diastole and systole
increases (Figure 2B). Importantly, as cardiac function is decreased the amount
of blood ejected in each cycle decreases, meaning a reduction in the amount of
cardiac output. The inability to maintain pump function is the definition of the
transition to HF (Kannel and Belanger 1991, Go, Mozaffarian et al. 2013).
Several important aspects of cardiac function can be studied using the
pressure-volume relationship including two critical concepts: the end-systolic and
end-diastolic pressure-volume relationships (ESPVR, EDPVR) (Figure 2C)
(Sagawa 1981, Kass, Yamazaki et al. 1986). The ESPVR is a linear relationship
that describes the contractile function of the heart. ESPVR is determined by
plotting the pressure-volume relationship at the end of systolic ejection (Point C)
in a series of cardiac cycles with alterations in preload or afterload. The slope of
the ESPVR line describes cardiac function by relating the preload volume
(reduced by occluding venous return) with how much blood was ejected (i.e.
contractility). In disease models with decreased contractility (e.g. HF without
preserved ejection fraction), the ESPVR is expected to have a shallower slope,
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meaning that the amount of blood pumped out during systole is lower than would
occur with a normal ESPVR for a given preload. Additionally, positive inotropic
drugs and signaling pathways that increase contractility result in a steeper
ESPVR slope and an increase in blood ejection (Suga and Sagawa 1974,
Sagawa 1981, Kass, Yamazaki et al. 1986).
The EDPVR describes how resistant the heart is to passive diastolic filling
by measuring how alteration in total filling volume of the ventricle at peak diastole
is related to the passive pressure found at peak diastole (Point A on the PVLoop). This is intuitive when thinking about how additional filling of the heart will
stretch the ventricle, with increased volume causing an increase in pressure as
the

heart

becomes

less

distensible.

In

disease

states

like

dilated

cardiomyopathy, the EDPVR has a rather flat slope, as increased filling of the
dilated and distensible ventricle causes an increase in volume with a smaller
increase in pressure. In contrast, during hypertrophy the increased fibrosis in the
myocardium results in decreased compliance and results in a steeper EDPVR,
as increased filling is met with greater resistance and causes pressure to rise
more rapidly (Sagawa 1981, Kass, Yamazaki et al. 1986).

2.1.4 Electrical Regulation of Contraction
The contraction of the right and left atria and ventricles occurs
concomitantly, with the coordinated contraction of the heart controlled by the
propagation of electrical signals through the myocardium. These signals begin in
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a specialized group of cells in the right atrium known as the sinoatrial (SA) node.
This node is comprised of pacemaker cells that set the heart rate autonomously
by initiating depolarization, and can be modulated by sympathetic and
parasympathetic inputs. When the SA node fires, it initiates a wave of
depolarization that spreads across the right and left atria, that causes their
contraction. As this depolarization spreads, it also travels from the SA node to
the atrioventricular (AV) node, which is located near the junction of the four
chambers, superior to the interventricular septum.
The AV node coordinates the contraction of the ventricles and has its own
latent pacemaker activity, such that if the SA node is injured or ablated the heart
will still rhythmically contract at the rate of AV node firing. The action potential
propagates from the AV node down specialized conduction fibers known as the
His-Purkinje system. These fibers run inferiorly through the interventricular
septum and then run from apex to base up the free walls of the left and right
ventricle. This conduction pattern allows both ventricles to contract in concert,
with the endocardium contracting slightly prior to the epicardium, and the apex
contracting before the base of the ventricle. This orientation and sequence of
contraction causes the ventricles to contract from the apex up, allowing efficient
ejection of blood from the ventricle. Action potentials also spread from cell-to-cell
due to the electrical coupling of cardiomyocytes via gap junctions (typically
Connexin 43 in ventricular tissue) that allow propagation of depolarization
through cells (Kreuzberg, Willecke et al. 2006).
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Hypertrophic remodeling of the heart can alter the electrical properties of
the myocardium and lead to arrhythmias and sudden cardiac death. As the tissue
thickens the wave of depolarization must travel further to activate all areas of the
heart. Furthermore the electrical properties of the tissue change in hypertrophy,
with alterations in gap junctions and ion channels influencing the propagation of
excitation (Sepp, Severs et al. 1996). Increased fibrosis in hypertrophy also
decreases the propagation of electrical current by increasing resistance. These
changes, along with certain alterations in the structure of the heart, such as
asymmetric hypertrophy, can create an environment that is arrythmogenic. These
situations have been speculated to be one of the contributing factors in sudden
cardiac death in patients with mild hypertrophy (Swynghedauw 1999, Maron,
Doerer et al. 2009).

2.1.5 Regulation of Cardiac Function
Regulation of heart rate (chronotropy), contractility (inotropy), and
relaxation (lusitropy) occurs via innervation of the heart as well as through
endocrine signaling. Regulation of the SA node is controlled by innervation from
sympathetic and parasympathetic neurons and alters heart rate, with sympathetic
innervation causing the heart to beat at an increased rate (Olshansky, Sabbah et
al. 2008). This is accomplished by increasing the rate of depolarization of the SA
node cells by increasing the funny channel (If) current, which allows more Na+
influx into the cell (DiFrancesco and Tortora 1991). In contrast parasympathetic
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innervation causes the SA node cells to depolarize more slowly by reducing the I f
current, therefore reducing the heart rate.
Positive inotropy and lusitropy is regulated primarily through sympathetic
innervation or pharmacological stimulation of the adrenergic signaling pathway
which involves agonist binding to the β-AR G-protein coupled receptor,
production of cyclic-AMP by adenylyl cyclase and activation of protein kinase A
(PKA). This kinase phosphorylates several targets in the cardiomyocytes
including numerous Ca2+ handling proteins, as well as several sarcomeric
proteins which will be discussed later. PKA phosphorylation of Ryanodine
Receptor (RyR) increases Ca2+ release into the cytosol, providing increased
contractility, although this remains controversial (Bers 2000, Marks 2000).
Phosphorylation of phospholamban relieves an inhibition on the sarcoplasmic
reticulum ATPase (SERCA), which allows SERCA to pump Ca2+ back into the
sarcoplasmic reticulum (SR) at a higher rate, which facilitates faster relaxation.
This also causes a positive inotropic effect as the SR is loaded with more Ca2+
for release in subsequent beats (MacLennan and Kranias 2003).

2.1.6 Excitation-Contraction Coupling
The sarcomeric machinery does not function without a cytosolic rise in
free Ca2+. Normal diastolic levels of Ca2+ in cardiomyocytes are in the range of
~100nM, whereas Ca2+ concentrations outside the cell are around 2mM, and in
the sarcoplasmic reticulum during diastole are in the 1mM range (Bers 2000).
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The series of events leading from cardiac action potential to the generation of
force is termed excitation-contraction (EC) coupling. This process begins with
depolarization of the cardiomyocyte, with depolarization spreading along the
sarcolemma and down the T-tubules, which are specialized invaginations of the
sarcolemma that penetrate into the cardiomyocyte. Depolarization of the T-tubule
membrane causes opening of L-type Ca2+ channels which allows an influx of
calcium into the cell. RyR Ca2+ channels are positioned in the sarcoplasmic
reticulum opposite of the L-Type Ca2+ channels. When calcium binds to the
cytosolic side of RyR, the channel opens and releases large amounts of Ca2+
from the sarcoplasmic reticulum. This event is known as calcium-induced calcium
release (CICR) (Figure 3).
During hypertrophic remodeling there is a general increase in β-AR
signaling, resulting in hyperphosphorylation of PKA targets (Heineke and
Molkentin 2006). These signaling changes cause greater Ca2+ release in the cell
during systole. However, if systolic free Ca2+ is increased for too long, diastolic
relaxation can be disrupted, leading to diastolic dysfunction as will be discussed
in regards to myofilament protein properties. Prolonged increases in diastolic
Ca2+ can also lead to arrhythmias as Ca2+ is extruded from the cell and alters
repolarization (Schober, Huke et al. 2012). Following chronic β-AR signaling,
desensitization can occur resulting in hypophosphorylation of many PKA targets.
This situation can result in a decline in contractility and further aberrations in Ca 2+
handling.

21

Figure 3 Simplified Excitation-Contraction Diagram.
A schematic diagram showing Ca2+ entry into the cardiomyocyte following
membrane depolarization. Calcium-induced calcium release (CICR) starts from
Ca2+ entry via L-Type Ca2+ channels which activates RYR Ca2+ release. This
activates the myofilaments (green and red lines). Following contraction Ca2+ is
taken back up into the SR via SERCA or extruded from the cell via NCX.
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2.1.7 Molecular Mechanisms of Sarcomere Contraction
Excitation-contraction coupling links the rise in intracellular Ca2+ to
development of force in the sarcomere. As a general overview, as these proteins
will be discussed later in greater detail, the sarcomere is comprised of thick
filaments containing myosin heavy chain (MHC), cardiac myosin binding proteinC (cMyBP-C), and titin. The sarcomeric thin filaments are composed of actin, αtropomyosin, and the troponin complex containing troponin C (TnC), troponin T
(TnT), and troponin I (TnI).
Excitation-contraction begins with the entrance of Ca2+ into the cell and
the release of calcium from the SR cause a rise in cytosolic Ca2+ as previously
discussed. The SR runs along the myofibrils and allows local Ca2+ concentrations
to increase. When Ca2+ binds to TnC it causes conformational changes in the
protein that transmit through TnT to actin and α-tropomyosin. This initiates
conformational changes that cause α-tropomyosin to alter its position along the
actin filaments, unmasking myosin binding sites on actin. The myosin motor head
is then able to bind weakly to the thin filament, establishing a cross-bridge
(Solaro 2009).
Sarcomere contraction is mediated by myosin’s ATPase activity that
occurs in a cyclic progression, using ATP for the energy of crossbridge cycling
and force generation (Rayment 1996). When the myosin heads have an empty
nucleotide binding site they remain tightly bound to the thin filaments. These
locked cross bridges are the molecular basis for rigor mortis following death as
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ATP levels are depleted, and binding of ATP to myosin causes dissociation from
the thin filament. The myosin ATPase then hydrolyzes ATP into ADP and
inorganic phosphate which causes a conformational change that allows myosin
to bind strongly with actin, as well as “primes” the myosin head for delivery of the
power-stroke. Upon acto-myosin crossbridge formation the Myosin ATPase
ejects the ADP and Pi from their binding sites, causing a conformational change
that generates the power-stroke. The myosin head remains attached until
another ATP molecule is bound, at which point the cycle repeats. The concerted
effort of crossbridge cycling results in sarcomere contraction and shortening,
which is the basis for cardiomyocyte contractility. A subset of HCM-causing
mutations in myosin have been identified; these mutations alter ATPase activity
and acto-myosin interaction, causing a direct impairment in force generation and
ATP usage (Sommese, Sung et al. 2013, Bloemink, Deacon et al. 2014).
Following force generation during systole, rapid relaxation of the
sarcomeres must occur to allow the heart to relax and fill with blood for the
subsequent beat. As the heart fills with blood during diastole, the left ventricle
distends

and

the

cardiomyocytes

are

stretched.

Increased

stretch

of

cardiomyocytes causes an increase in contractility due to the Frank-Starling Law
of the Heart (de Tombe, Mateja et al. 2010). This is a functionally useful property
for the heart, as it allows the heart to contract harder when it is filled with more
blood, regulating cardiac function on a beat-to-beat basis without changes in
heart rate or requiring alterations in signaling pathways. The molecular basis for
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the Frank-Starling Law is due to the length-dependent increases in sarcomere
Ca2+ sensitivity which causes increased force development at a given Ca2+
concentration. This is observed in single cells where a stretched sarcomere will
generate more force than an un-stretched sarcomere (Konhilas, Irving et al.
2002). This effect has an upper limit, where additional stretch will produce no
additional force, and indeed excess stretch results in decreased force generation
due to physical deformation of the sarcomeric machinery. Despite the importance
of length dependent activation in regulating cardiac function, the mechanism by
which it alters Ca2+ sensitivity and regulates force generation is still being
determined.
Due to the importance of length-dependent changes in Ca2+ sensitivity of
force development, the work outlined in this study used skinned cardiomyocytes
to assess this effect. As will be discussed later, alterations in myofilament
proteins can alter Ca2+ sensitivity of force development, and haploinsufficiency of
cardiac myosin binding protein-C may alter these parameters.

2.1.8 Etiology of Hypertrophic Cardiomyopathy
In the previous sections the many physiological functions of the heart have
been described, as well as some of the perturbations that occur during the
development of cardiomyopathy. While some functional alterations that occur in
HCM have been highlighted in the previous sections, the etiology, prognosis, and
treatment of HCM must be examined in order to understand the complexity of
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this pathology.
Hypertrophic cardiomyopathy is a prevalent inherited pathological
enlargement of the heart that was originally described in 1958 (Teare 1958)
(Maron, Gardin et al. 1995). This disease involves hypertrophy of the left
ventricle, in some cases with disproportionate hypertrophy of the interventricular
septum, termed asymmetric hypertrophy. A diagnosis of HCM requires an
absence of causes of hypertrophic remodeling such as diabetes, high blood
pressure, or infarcted tissue (Spirito, Seidman et al. 1997, Go, Mozaffarian et al.
2013). As hypertrophy in HCM does not occur in response to an external
stimulus it was classically defined as idiopathic cardiomyopathy. In the 1990’s
this

idiopathic

heritable

HCM,

also

known

as

familial

hypertrophic

cardiomyopathy was determined to be a disease of the cardiac sarcomere, with
mutations in several sarcomeric genes identified as the heritable causes of the
disease, which will be described later.
At the level of the whole organ, physiological hypertrophy, as occurs
following aerobic training, involves growth of the heart muscle outwards with a
preserved ventricular internal diameter and increased contractile performance
(Swynghedauw 1999). However, in pathological hypertrophy the myocardium
hypertrophies inward, reducing the volume of the ventricle. During hypertrophy,
the heart typically retains the ability to pump blood, with a maintained ejection
fraction and normal cardiac output.
One hallmark of HCM is the development of diastolic dysfunction that can
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occur for various reasons, including reduction in left ventricular compliance due
to increased wall thickness and increased fibrotic remodeling. Diastolic
dysfunction prevents normal relaxation, which, along with the reduced ventricular
volume, causes reduced filling of the ventricle (Nagueh, Appleton et al. 2009).
Following pathological hypertrophy in mice, and in a subset of human HCM
cases (approximately 10%), progression to DCM can occur. This typically
accompanies the onset of HF, with morphological changes including thinning of
the ventricle walls, resulting in reduced force generation, and dilating of the left
ventricle (Figure 4).
In mice the progression from pathological hypertrophy to dilation is an
important morphological indicator of development of HF, despite the fact that this
transition from HCM to DCM to HF is not commonly observed in humans (Kannel
and Belanger 1991, Olivotto, Cecchi et al. 2012). Therefore, in the work detailed
in this dissertation periodic monitoring of ventricular morphology was done using
echocardiography to assess the progression of disease.
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Figure 4. Cardiac Morphology in Health and Disease.
This schematic illustrates that during physiological hypertrophy the heart
enlarges proportionally, adding myocardium with preserved luminal space.
Pathological hypertrophy results in an increased wall thickness and reduced
internal diameter. During dilation the walls of the heart thin and begin to lose the
ability to generate force for sufficient ejection of blood, while the ventricular
volume increases.
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At the cellular level remodeling of the cardiomyocyte contractile machinery
also occurs in HCM. During hypertrophy the cardiomyocytes start to produce
additional sarcomeres. However, unlike physiological hypertrophy, these new
sarcomeres are added in deranged patterns which result in less coordinated
contraction and less efficient force development (Arad, Seidman et al. 2002).
Despite the inefficiency of hypertrophic remodeling, hypertrophic hearts can
maintain pump function for prolonged periods. However, for reasons that are still
being studied, functional decompensation can occur, leading to heart failure with
preserved or impaired ejection fraction and insufficient cardiac output. These
hearts are unable to efficiently exert force on the blood in the ventricle, which
results in reduced ejection fraction and impaired cardiac output. The transition to
dilation in mice and human patients with dilation often accompanies the transition
to heart failure (Teare 1958, Olivotto, Cecchi et al. 2012).
During the development of hypertrophy, fibroblasts increase the deposition
of extracellular matrix, causing increased fibrosis of the heart. The mechanisms
governing

fibrotic remodeling are

still being deciphered; however, as

cardiomyocytes die they are replaced by fibroblasts (Varnava, Elliott et al. 2000).
Increased collagen and connective tissue deposition increases the fibrous nature
of the myocardium and remodeling of normal extracellular matrix increases the
proliferation of fibroblasts (Ho, Lopez et al. 2010). This reduces the compliance
of the ventricle as a whole, and has adverse effects on cardiac performance as
diastolic filling becomes more difficult (Nagayama, Takimoto et al. 2007).
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Another common complication of HCM is sudden death, which tends to
occur in younger carriers of HCM mutations and typically occurs during high
levels of exertion (Maron, Roberts et al. 1980, Maron, Doerer et al. 2009).
Victims of sudden death often have a mildly hypertrophic phenotype and in many
cases were unaware of any pathology (Maron, Doerer et al. 2009). The cause of
sudden death in these patients is unclear, but it has been suggested that
alterations in conduction pathways in the hypertrophied myocardium provide the
opportunity for arrhythmias to develop, especially at high heart rates, and can
lead to ventricular fibrillation and death (Schober, Huke et al. 2012). While this
provides a general explanation for how hypertrophy causes sudden cardiac
death, some specific HCM-causing mutations in the troponin complex have been
established to cause alterations in Ca2+ handling in the myocyte and can cause
the development of arrhythmia directly (Knollmann, Kirchhof et al. 2003,
Schober, Huke et al. 2012).
Effective treatment of HCM is complicated due to the diverse causes of
hypertrophy, especially in treating genetic HCM compared to treating a
hypertrophic stimulus, such as blood pressure. In cases of HCM caused by
mutations in sarcomeric proteins, interventions are currently only available to
treat the phenotype, while the primary cause is unaddressed. In cases of
asymmetric hypertrophy, where septal enlargement has partially occluded the
aortic outflow tract, use of septal ablation has been recently shown to improve
function (Olivotto, Ommen et al. 2007). This technique removes portions of the
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septal myocardium by surgical excision or by destroying the tissue with ethanol
injection (Olivotto, Ommen et al. 2007).
The dilemma for producing a viable treatment for familial cardiomyopathy
is that each mutation may have a unique mechanism of action and require a
different treatment strategy. The difficulty of viable treatment is demonstrated by
the different causes of HCM in patients with myosin heavy chain or cMyBP-C
mutations, with myosin mutation carriers developing HCM typically with a more
severe phenotype and worse prognosis (Arad, Seidman et al. 2002). The
majority of myosin heavy chain mutations result in a protein with aberrant
function, whereas cMyBP-C mutations predominantly result in a lack of viable
protein. This necessitates different strategies to address these two types of
mutations at the molecular level. Gene therapy has been employed in mouse
models carrying mutations in both myosin and cMyBP-C and has shown some
positive results (Cheng, Wan et al. 2013, Jiang, Wakimoto et al. 2013). These
strategies focus on either expressing a gene that is not expressed in suitable
quantity (i.e. to treat a haploinsufficiency-based disease) or to knock-down a
mutant protein product that exerts a pathological effect (i.e. to treat a poison
polypeptide). Therefore, it is imperative that the mechanisms by which these
mutations exert a pathological phenotype are determined in order to guide any
potential future therapies.
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2.1.9 Heart Failure
Heart failure is a common end point for a number of cardiovascular
diseases. Clinically, heart failure is defined by the inability of the heart to supply
enough blood to meet the body’s demands (Go, Mozaffarian et al. 2013). HF is a
life threatening condition and despite the alarming and acute sounding nature of
the disease’s name, a patient can live with clinical heart failure for years with
various reductions in quality of life. In fact, a patient with early heart failure may
show few signs of any physical abnormalities when resting. However, a typical
feature of HF is exercise intolerance, when an individual’s heart may be able to
perform suitably under resting conditions, but upon increased cardiac demand
the heart is unable to provide sufficient perfusion for proper oxygen delivery. HF
patients typically suffer from fatigue due to this reason, and as the disease
progresses, more routine tasks become impossible. During the progression of HF
cardiac function will decline until even the most basic demands on the heart are
unable to be met, leading to death (Go, Mozaffarian et al. 2013).
Heart failure defines a condition that can come about as the result of
several

pathologies.

As

discussed

previously,

familial

hypertrophic

cardiomyopathy can cause reduced cardiac function that can ultimately result in
HF. This is also true of other pathologies that cause a reduction in cardiac
function such as hypertensive hypertrophy, diabetic cardiomyopathy, and
necrosis of myocardial tissue caused by ischemia-reperfusion injury or
myocardial infarction. All of these diseases can cause decreases in cardiac
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function until HF develops (Swynghedauw 1999).
Despite the high prevalence and poor prognosis of HF, effective
treatments for this disease remain elusive. Research has focused on determining
the molecular mechanisms which lead to the development of HF with the
intention to mitigate or reverse the progression of the disease. Unfortunately,
once HF has developed treating this disease and reversing the dysfunction has
proven difficult. The optimal clinical approach to treating HF is to prevent its
onset in the first place. This is obviously difficult to accomplish, and realistically
approaching the management of HF in this way requires a firm understanding of
the risk factors and etiology of the diseases leading to HF (Kannel and Belanger
1991).
One of the major treatments for end-stage HF is heart transplantation,
which is not an ideal treatment strategy due to the paucity of viable donor hearts
and issues with donor-recipient compatibility (Hunt, Baker et al. 2001). Recent
advances made in the development of cheaper, more effective left-ventricular
assist devices (LVADs) have proved effective in treating HF by reducing the
work-load on the heart. Patients receiving LVADs have shown improved energy
levels and quality of life (Slaughter, Rogers et al. 2009). Interestingly, a subset of
patients who have received an LVAD and subsequently had the device removed
have shown reversal of some of the adverse remodeling of the heart, with
increased cardiac function and patient quality of life (Slaughter, Rogers et al.
2009). While this finding is fascinating, the efficacy of LVAD as actual treatment
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for HF is unclear and the high cost of the devices make them an unfeasible
treatment for the millions of patients suffering from HF.
The clinical treatment of HF has focused on managing symptoms and
increasing the patient’s physical capacity (Hunt, Baker et al. 2001). Therapies
such as using diuretics to reduce blood volume, or β-AR signaling blockade (βBlockers) to help reduce blood pressure by reducing the contractility of the heart,
both act to treat symptoms of HF, such as congestion. Although pharmacological
treatments can improve cardiac function and symptoms in the short-term, they do
not serve as treatments of the underlying pathology, and patients will still
progress into worsened HF with time unless the underlying causes can be
addressed (Hunt, Baker et al. 2001).
A treatment for HF that has shown promise in clinical trials is the use of
gene therapy. Virally mediated gene therapy using recombinant SERCA protein
in human myocardium has been effective for increasing cardiac performance by
increasing the rate of Ca2+ reuptake into the SR. This also improves systolic
function due to increased systolic SR Ca2+ release causing increased contractility
(Miyamoto, del Monte et al. 2000, del Monte, Williams et al. 2001). While the
long-term efficacy of this and similar gene therapy approaches have yet to be
demonstrated, efficacious treatment for advanced HF may have tremendous
potential as technical limitations such as maintaining gene expression and
efficacious delivery routes are overcome. The potential for using these
techniques for treating HCM makes identifying the molecular mechanisms that
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lead to hypertrophy and HF critical, as this knowledge will be immediately
applicable to in the development of future genetic therapy.

2.2 HCM: A Disease of the Cardiac Sarcomere
As sarcomere dysfunction and mutations in genes encoding sarcomere
proteins have been shown to cause HCM, it is critical to understand the
composition, function, and regulation of the cardiac sarcomere. The functional
unit of the cardiomyocyte contractile machinery is the sarcomere. Single
sarcomeres are arranged end-to-end to form long myofibrils that run the length of
the cardiomyocyte. The concerted shortening of the sarcomeres causes
contraction of the cell which in turn results in contraction of the heart. The single
sarcomere is made up of numerous thin and thick filaments arranged parallel to
each other that contain all the proteins responsible for contraction and relaxation
of the sarcomere. Structures called Z-discs bookend the contractile machinery
and demarcate a single sarcomere (Figure 5). From the Z-discs, thin filaments
extend inwards towards the M-line, the midline of the sarcomere, while the
myosin thick filaments originate at the M-line and extend outwards towards the Zdiscs. This arrangement gives polarity to both filament types, and when
actomyosin crossbridge cycling occurs, both Z-discs are brought closer together.
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Figure 5 Schematic diagram of the cardiac sarcomere.
Depiction of parallel interdigitated thick and thin filaments located between Zdisks with mirrored orientation on either side of the M-line. Actomyosin overlap
occurs in the A band, with cMyBP-C occupying axial stripes in a subset of the A
band, termed the C-zone (Barefield and Sadayappan 2010).
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2.2.1 The Z-Disks
The Z-disks of the sarcomere are structurally comprised of antiparallel
dimers of α-actinin, although numerous other regulatory proteins also are located
in this structure (Sjoblom, Salmazo et al. 2008). The α-actinin proteins in the Zdisks bind to the actin thin filaments, attaching them to the Z-disks where the
actin filament is capped. The giant sarcomere protein titin is also connected to
the Z-disks through α-actinin binding. The sarcomeres are anchored to the cell
via the intermediate filament desmin, which is thought to bind to the Z-disks (Witt,
Burkart et al. 2006). Desmin also links to ankyrin proteins in the sarcolemma and
helps stabilize and organize the sarcomeres into well-ordered bundles (Tonino,
Pappas et al. 2010). The Z-Disks also serve as localization points for a variety of
signaling molecules. This includes anchoring of PKA and PKC, as well as the
Ca2+ responsive phosphatase calcineurin (Pyle and Solaro 2004).
The Z-disk has also been implicated as a sensor for sarcomere strain and
is thought to play a role in the development of hypertrophy. While several prohypertrophic signaling molecules, such as PKA, are localized at the Z-disk, the
presence of calcineurin and its repressor protein four and a half LIM domains 2
(FHL2) in the Z-disk has been suggested as a critical component of hypertrophic
signaling following stress (Nordhoff, Hillesheim et al. 2012). Indeed, when
activated by Ca2+/calmodulin, calcineurin dephosphorylates the pro-hypertrophic
transcription factor NFAT, leading to its nuclear localization and activation of
hypertrophic remodeling (Molkentin, Lu et al. 1998).

37
2.2.2 The Thick Filament
The sarcomeric thick filaments are primarily composed of the motor
protein myosin heavy-chain, with the slow β isoform predominant in human
hearts and the fast α isoform as the main isoform in mouse hearts. The myosin
molecule has a long filamentous tail region (light meromyosin, or LMM) and
forms a coiled coil dimer that incorporates to form the body of the thick filament.
Groups of myosin heavy-chain dimers are bundled together to form the thick
filament backbone, resulting in a filament that has a staggered helix of myosin
heads every 14.3 nm, with a 43 nm helical turn distance (Craig, Lee et al. 2014) .
Myosin also has a motor head domain that extends away from the LMM
backbone of the thick filament and contains the ATPase activity-containing
subunit responsible for force generation. The neck and head region of myosin
also bind the accessory proteins myosin essential light chain (ELC) and myosin
regulatory light chain (RLC), such that each functional myosin dimer consists of
two myosin heavy chains (LMM and the head region), two ELCs and two RLCs
(Poetter, Jiang et al. 1996).
The protein titin is attached to the myosin thick filament, which is anchored
to the Z-disk protein, α-actinin, and to the actin thin filament at its N’-terminal
region and runs to the M-line of the sarcomere (Pyle and Solaro 2004). Titin
provides the major elastic component of the sarcomere and is one of the
determinants of the level of resting tension in a cardiomyocyte (LeWinter and
Granzier 2010). Titin’s C’-terminal region occupies the A band and is composed
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of 11 non-elastic immunoglobulin and fibronectin like super repeats. The
periodicity of these super repeats along the barrel of the thick filament has been
suggested to help organize sarcomere proteins along the thick filament and act
as a molecular ruler for sarcomere assembly (Labeit and Kolmerer 1995). In the
cardiac sarcomere titin can be found in three splice variants. The N2B titin
isoform contains normal elastic components and is the most widely expressed in
adult sarcomeres. The larger N2BA titin has additional elastic elements and is
considerably longer than N2B titin, resulting in lower passive tension in
experimental models with this isoform predominantly expressed. The third splice
variant category consists of several variants that are predominantly expressed in
fetal development and do not normally occur in adult cardiomyocytes (Bang,
Centner et al. 2001).
Another major thick-filament protein is cMyBP-C, which will be discussed
in detail later. In brief, cMyBP-C interacts with the thick filament proteins LMM
and titin via binding sites at its C’-terminus (Figure 6) (Okagaki, Weber et al.
1993). The exact organizational arrangement of cMyBP-C’s binding to the thick
filament is currently unclear. A body of evidence supports a strut model, where
the C’-terminal residues of cMyBP-C run parallel along the thick filament, with
their N’-terminal residues extending out into the interfilament space where they
can interact with the myosin S2 region and actin. Other evidence suggests that
the C’-terminal domains of cMyBP-C wrap around the thick filament like a collar,
with three cMyBP-C molecules forming a ring around the thick filament and also
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interacting with each other. This model also posits that the N’ regions of the
protein extend into the interfilament space and interact with Myosin S2 and actin.
However, direct evidence has demonstrated that cMyBP-C’s C’ residues are 10
nm closer to the M-line than its C0-C5 domain, which is consistent with three C’
residues running parallel down the thick filament and supports the strut model
(Craig, Lee et al. 2014).
Alterations to the thick filament, often from a genetic basis, have been well
established to cause cardiomyopathy. Specific mutation effects on sarcomere
function will be discussed in detail later; however, it is important to note that
alterations in thick filament assembly, regulation by phosphorylation, and myosin
motor activity can cause deficits in relaxation and force development. An
example of this dysfunction has been observed in a well-studied MHC mutation
(R403W) that exhibits an enhanced ATPase activity without a concomitant
increase in force, meaning that this mutation causes the myosin motor to work
less efficiently (Keller, Coirault et al. 2004).
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Figure 6. Molecular Schematic of a Single Crossbridge.
Myosin/titin thick filaments run parallel to decorated actin thin filaments, with the
myosin head extending into the interfilament space. Cardiac MyBP-C interacts
with the LMM domain of myosin and Titin via its C’-terminal domains and
interacts with the myosin head and actin via its N’-terminal domains.
Phosphorylation of identified sites on cMyBP-C have been proposed to modulate
its interaction with its N’-terminal binding partners by altering the affinity of the N’terminal region for myosin S2 and Actin, regulating crossbridge cycling (Barefield
and Sadayappan 2010).
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2.2.3 The Thin Filament
The thin filaments of the sarcomere are principally comprised of long
helical actin chains. Actin is a globular monomeric protein that can polymerize
into filaments of various lengths. These filaments form a coiled-coil with two actin
filaments coiled around each other, with seven actin monomers per single actin
filament per half-turn. In the sarcomere these filaments are anchored at the Mline via the structural protein α-actinin (Sjoblom, Salmazo et al. 2008).
Sarcomeric actin filaments are decorated by several other proteins that
regulate sarcomere function. The regulatory protein α-Tropomyosin lies in the
cleft between actin monomers and runs along the thin filament in this groove. αtropomyosin also exists as a coiled-coil dimer and one dimer runs along the actin
filament for half a helical turn. Chains of α-tropomyosin are formed along the thin
filament by head-to-tail binding to other α-tropomyosin dimers (Mun, Previs et al.
2014).
Along the thin filament the heterotrimeric troponin protein complex binds to
α-tropomyosin and actin. The troponin complex is composed of three troponin
proteins, all with an individual function. Troponin T (TnT) binds to α-tropomyosin
and actin, and anchors the troponin complex to the thin filament. Troponin I (TnI)
has an inhibitory function on thin filament activation, which will be discussed
later. Troponin C (TnC) contains the Ca2+ binding domain of the troponin
complex and is responsible for initiating molecular changes that occur following
Ca2+ binding (Parmacek and Solaro 2004).
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2.2.4 Regulation of Sarcomere Function
The function of the sarcomere can be dynamically regulated by a number
of signaling pathways. The β-adrenergic pathway begins at the plasma
membrane with the binding of norepinephrine (or a β-AR agonists) to the β-AR
G-Protein coupled receptor, causing the activation of adenylyl cyclase and the
production of cyclic AMP (cAMP), which activates protein kinase A (PKA) (Dorn
and Force 2005). PKA is able to phosphorylate several sarcomeric proteins with
the concerted effect of increasing inotropy and lusitropy. PKA targets cTnI by
phosphorylating serine 22/23 in humans (23/24 in mouse), which alleviates the
inhibitory effects of cTnI, resulting in a decrease in Ca2+ sensitivity of the
myofilaments. This allows faster displacement of Ca2+ during diastole, leading to
faster relaxation (Frazier, Ramirez-Correa et al. 2011). Phosphorylation of serine
273, 282, and 302 (mouse) of cMyBP-C regulates crossbridge cycling rates,
allowing for faster contraction and relaxation kinetics and increased force
generation (Tong, Stelzer et al. 2008). Titin phosphorylation by PKA is
associated with reduced stiffness of the myofilaments, facilitating faster
relaxation during diastole (Kotter, Gout et al. 2013).
Alterations in signaling occurring through increased mechanical stress or
signaling via various pathways (e.g. angiotensin, norepinephrine) can cause a
rise in cardiomyocyte Ca2+ and have been associated with both physiological and
pathological hypertrophic remodeling (Dorn and Force 2005). This increase in
Ca2+ triggers the calcineurin pathway (as mentioned previously) and can activate
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protein kinase C (PKC) through Ca2+ binding or via diacylglycerol from
phospholipase-C activity (Nishizuka 1986). In the myofilaments, it has been
observed that PKC-mediated phosphorylation of cTnT and cTnI reduces
contractility, and treatment of skinned cardiomyocytes with PKC results in
decreased force generation and decreased Ca 2+ sensitivity of force development
(Belin, Sumandea et al. 2007).
Another kinase that has been established to play a role in myofilament
signaling and contractility is CaMKII. The isoform predominantly expressed in the
heart is calcium-calmodulin kinase II delta (CaMKIIδ), with a nuclear-localized
variant responsible for hypertrophic gene expression and a cytosol-localized
variant that is responsible for phosphorylation of the myofilament proteins
(Zhang, Maier et al. 2003). CaMKII has been suggested to act in response to
increased Ca2+ concentrations by activating a number of transcription factors,
including myocyte enhancer factor 2 (MEF2), that are pro-hypertrophic (Passier,
Zeng et al. 2000). CaMKII has been reported to target SERCA/phospholamban,
L-type Ca2+ channels and RyR, with a net effect of causing increased SR Ca2+
leak, although the effect of these regulatory modifications remain controversial
(Zhang, Maier et al. 2003). Interestingly, CaMKII has been shown to
phosphorylate cMyBP-C in vitro, with decreased CaMKII phosphorylation
associated with decreased contractility (Tong, Gaffin et al. 2004).
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2.2.5 Sarcomere Protein Mutations
Hundreds of mutations in sarcomeric proteins have been linked to the
development of HCM and DCM (Table 1). Even with this number of mutations
described, roughly a third of cardiomyopathies remain idiopathic, with no
currently described mutations. Of the mutations that result in cardiomyopathy,
mutations in myosin (MYH7) and cMyBP-C (MYBPC3) each comprise around 3040%. The other described mutations mostly occur in other myofilament proteins.
It has been suggested that Titin, due to its enormous size may be a significant
contributor to HCM and DCM mutations, although mutations in this gene have
not been studied until recently (Golbus, Puckelwartz et al. 2012, Herman, Lam et
al. 2012). The exact mechanisms by which these mutations exert a pathological
effect are still under investigation and vary depending on the specific mutation.
However, while most of these effects are currently poorly understood, these
mutations can be grouped into a few general categories.

.
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Table 1. Currently Identified HCM and DCM Associated Sarcomere Gene
Mutations
This table reports the number of identified mutations associated with HCM and
DCM found in genes encoding proteins of the cardiac sarcomere. Updated from
(Barefield and Sadayappan 2010) with (Harris, Bartley et al. 2002, Herman, Lam
et al. 2012).
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2.2.6 The Poison Polypeptide Mechanism
Mutations in the gene for myosin heavy chain (MHC, predominantly
encoded by the MYH7 gene in human adults) have been identified to be
missense mutations that result in the substitution of one amino acid for another.
Due to the requirement of functional myosin for the development of a viable
organism, it is understandable why drastic mutations, such as mutations causing
exon skipping or frame shifts, would be lethal in the myosin gene. As such, the
identified MHC mutations are typically amino acid substitutions that cause a
mechanistic impairment in myosin function that does not prohibit myosin from
functioning in sarcomere assembly. The point mutations studied in MHC have
shown that slight alterations in myosin’s ability to interact with regulatory proteins
or in functionally critical regions can cause a decline in function, development of
cardiomyopathy and progression to HF. Indeed, mutations in MYH7 are often
associated with a more severe phenotype and poorer outcomes for the patients
than are mutations in other sarcomeric proteins (Bloemink, Deacon et al. 2014).
In these mutations a protein is expressed that exerts a dominant negative
effect that acts as a poison polypeptide. As this disease mechanism is based on
the expression of a mutant protein, treating this pathology may be possible by
knocking down the mutant allele specifically. Some interesting progress has been
made on this front recently by the Seidman lab, where allele-specific siRNA was
employed in a heterozygous mouse model of the well-studied myosin heavy
chain R403Q mutation (studied in the mouse MYH6 gene instead of the human
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MYH7 gene) via adeno-associated virus delivery to good effect (Jiang, Wakimoto
et al. 2013). However, this approach has applicability only in mutations with an
expressed protein product, and is difficult in that specific targeting of a mutant
allele is challenging, but does show promise for treating cardiomyopathy as well
as other diseases caused by missense mutations.

2.2.7 The Haploinsufficiency Mechanism
In contrast, mutations in the gene MYBPC3 have been suggested to
cause cardiomyopathy through a different mechanism. Of the currently identified
cardiomyopathy-associated

MYBPC3

mutations,

approximately

70%

are

expected to code for a protein that is missing its C’ region (Barefield and
Sadayappan 2010). This occurs in most cases due to mutations that cause exon
skipping and frame shifts, with the inclusion of novel stop codons. As the C’terminal region of cMyBP-C is required for incorporation into the sarcomere,
these mutant proteins are not typically detected in tissue from mutant carriers. As
the pathological mechanism in this case may involve insufficient expression of
cMyBP-C, gene therapy approaches have been tried to correct this deficit.
Recently, work from the Stelzer lab described a promising experiment using
adenoviral expression of MYBPC3 in a heterozygous mouse with decreased
cMyBP-C content, resulting in some functional improvements (Cheng, Wan et al.
2013).
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2.2.8 Other Pathological Mechanisms in Sarcomere HCM Mutations
Studies aiming to understand the mechanism by which mutations in other
sarcomeric proteins exert a pathological effect are also ongoing. These
mutations depend on the specific protein and the type of mutation. For example,
a group of mutations in troponin T that cause HCM and cardiac sudden death
have been established to act via calcium sensitization of the myofilament,
causing disruption of normal calcium cycling and increasing the propensity for
arrhythmias (Knollmann, Kirchhof et al. 2003, Schober, Huke et al. 2012).
Due to its enormous size, mutations in the gene encoding the sarcomeric
protein titin (TTN) have been understudied. Recent analysis has revealed that
mutations in TNN are found in 25% of cases of idiopathic familial DCM. These
findings provide an onus to examine the possibility of TNN mutations in HCM, as
nearly a quarter of familial HCM cases remain idiopathic with no causative
mutations identified, although currently titin mutations seem to only result in DCM
phenotypes (Herman, Lam et al. 2012).

2.2.9 Discovery of New HCM Linked Mutations
Following the discovery that familial HCM was often caused by mutations
in certain sarcomere proteins, screening for known and novel mutations in these
genes became routine. Initially, screening panels were limited to known HCM
associated genes, such as MYH7 and MYBPC3, with the addition of some novel
genes. Eventually screening for these mutations began to use arrays, which
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investigated 50 or so known and novel genes (Puckelwartz and McNally 2014).
An understandable consequence to screening in this manner is that novel
HCM associated genes are unlikely to be sampled by such a limited panel. Also,
known HCM genes that have been screened routinely for over a decade will have
numerous new variants identified. A complication of this approach is that
discovery of a potentially pathogenic single-nucleotide polymorphism (SNP) in a
known HCM related gene may not be the responsible, or the only responsible
mutation in the development of HCM. However, once a SNP in a known
cardiomyopathy-associated gene is discovered, further screening has not
historically been performed (Christodoulou, Wakimoto et al. 2014, Puckelwartz
and McNally 2014).
With the development of next-generation sequencing technology, the
sequencing of whole genomes, exomes, and transcriptomes has become
considerably more feasible in clinical practice and basic science laboratories.
Screening patients with family histories of HCM, using whole-exome or wholegenome techniques, allows identification of potentially pathogenic mutations in
known HCM-associated genes, as well as mutations in novel genes (Puckelwartz
and McNally 2014, Golbus, Puckelwartz et al. 2012). In addition, recent use of
these

techniques

has

allowed

identification

of

novel

modifiers

of

cardiomyopathies (Christodoulou, Wakimoto et al. 2014). In this study, the use of
whole-transcriptome RNA-sequencing methods were employed to assess novel
changes in gene expression in heterozygous MYBPC3 mutant-carrying mice

50
(Christodoulou, Gorham et al. 2011). The power of this technique is its ability to
assess changes in the transcriptome without needing to identify a specific
candidate a priori.

2.3 Cardiac Myosin Binding Protein-C
Cardiac MyBP-C is a 140 kDa sarcomeric thick-filament protein that binds
to myosin. This protein was originally described by Offer et al, 1973 when it was
discovered as a major contaminant in myosin extracts. It is found exclusively in
the vertebrate heart and is encoded by the gene MYBPC3. It is localized in the
inner two-thirds of the A band, and gives rise to the name for its zone of
localization: the C-zone (Yamamoto and Moos 1983, Fougerousse, Delezoide et
al. 1998, Niimura, Bachinski et al. 1998). Antibody staining shows that cMyBP-C
is restricted to the outer 7 to 9 axial bands, depending on the tissue type, with 9
bands found in the heart, spaced approximately 43 nm apart in each C-zone
(Figure 5) (Luther, Bennett et al. 2008).
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Figure 7. Domain Structure of Mouse cMyBP-C.
There are eight immunoglobulin-type (Ig) and three fibronectin-type (Fn3)
domains numbered C0 to C10. The cardiac isoform of MyBP-C has a specific
domain (C0) at the N-terminus and a specific sequence insertion in C5. The ProAla-rich domain, M-domain, and interacting sites with actin, myosin and titin are
shown. The M- domain contains 3 sites that can be phosphorylated by various
kinases including PKA, PKD, RSK, CAMKII, and PKC. These amino acid
sequences are conserved between mice and humans. The red arrow shows the
major proteolytic cleavage site of the calpain protease. The truncation mutant
used in this proposal contains an insertion of novel residues in domains C9 and
C10, which disallow strong interaction with myosin and titin, preventing proper
incorporation into the sarcomere (Barefield and Sadayappan 2010).

52
2.3.1 Molecular Structure and Localization of cMyBP-C
Cardiac MyBP-C consists of 11 domain modules, labeled C0 to C10 from
the N to the C-terminus, (Figure 7) and is composed of repeating
immunoglobulin and fibronectin type-3 domains. Cardiac MyBP-C interacts with
the S2 fragment of myosin via its M-domain in a phosphorylation dependent
manner; such that when cMyBP-C is dephosphorylated it binds tightly to the
myosin S2 region, whereas after phosphorylation the M-domain does not interact
with myosin S2 and instead has been shown to be able to interact with actin
(Gruen and Gautel 1999, Sadayappan, Osinska et al. 2006, Shaffer, Kensler et
al. 2009). Cardiac MyBP-C is strongly anchored to LMM via its C10 domain,
(Gilbert, Cohen et al. 1999) and titin via the C8-C10 domains (Freiburg and
Gautel 1996). In addition, a potential actin-binding sequence exists in the ProAla-rich linker sequence located between the C0 and C1 domains, (Shaffer,
Kensler et al. 2009) and there is evidence for in vitro interaction between cMyBPC and actin via the C0 domain, (Kulikovskaya, McClellan et al. 2003) C1 and Mdomain, (Shaffer, Kensler et al. 2009) and C5 domain (Rybakova, Greaser et al.
2011). It has also been shown that cMyBP-C can interact and alter the action of
α-Tropomyosin (Mun, Previs et al. 2014).
Cardiac MyBP-C modulates myosin assembly (Offer, Moos et al. 1973)
and stabilizes the thick filaments, (Moos, Mason et al. 1978, Squire, Luther et al.
2003) which is important for the precise arrangement of actin-myosin filaments in
the sarcomere. These studies indicate that the N’-terminal region of cMyBP-C is
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critical for sarcomere stability. It has been shown that the N’-regions are severely
degraded during myocardial injury, which will be further addressed later (Decker,
Decker et al. 2005, Sadayappan, Osinska et al. 2006).

2.3.2 Phosphorylation Mediated Regulation
A feature of the cardiac specific isoform of MyBP-C is its multiple
phosphorylation sites (Yuan, Guo et al. 2006). Cardiac MyBP-C is extensively
phosphorylated under basal conditions in mice and humans; however, the level
of cMyBP-C phosphorylation is altered in mouse models during development of
HF, I-R injury, pathologic hypertrophy, (Sadayappan, Gulick et al. 2005)
myocardial stunning (Squire, Luther et al. 2003, Yuan, Guo et al. 2006) and in
human patients with atrial fibrillation (El-Armouche, Boknik et al. 2006). Three of
the serine residues in cMyBP-C (mouse Ser-273, Ser-282 and Ser-302) are
differentially phosphorylated by the enzymes PKA, PKC, protein kinase D (PKD),
ribosome s6 kinase (RSK) and CaMKII (Fig. 7) (Gautel, Zuffardi et al. 1995,
Mohamed, Dignam et al. 1998, Bardswell, Cuello et al. 2010, Cuello, Bardswell
et al. 2011). Recent evidence also established that glycogen synthase kinase 3
beta (GSK3β) phosphorylates cMyBP-C in the Pro-Ala-rich linker region on Ser133 (Ser-128 in mice) (Kuster, Sequeira et al. 2013). During the development of
HF, total phosphorylation of cMyBP-C is decreased, with a major loss of triphosphorylated protein (Decker, Decker et al. 2005, Sadayappan, Gulick et al.
2005). Reduced phosphorylation is accompanied by contractile dysfunction,
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reduced force generation, and increased cleavage of cMyBP-C (Decker, Decker
et al. 2005, Sadayappan, Osinska et al. 2006).
Previous studies have shown that cMyBP-C phosphorylation by PKA
regulates myocardial function (Sadayappan, Gulick et al. 2005, Sadayappan,
Osinska et al. 2006, Nagayama, Takimoto et al. 2007, Sadayappan and Robbins
2008, Sadayappan, Gulick et al. 2009) and confers resistance to proteolysis and
protection against I-R injury (Sanada, Asanuma et al. 2004, Sadayappan,
Osinska et al. 2006, Sadayappan, Gulick et al. 2009). It has also been shown
that degradation of cMyBP-C correlates well with contractile dysfunction (Decker,
Decker et al. 2005, Sadayappan, Osinska et al. 2006). Transgenic expression of
phospho-ablated (Ser substitution to Ala mutations) cMyBP-CAllP- causes
functional deficits at the whole-heart level and leads to impaired hemodynamics
(Sadayappan, Gulick et al. 2005). Conversely, the phospho-mimetic (Ser
substitution to Asp) cMyBP-CAllP+ replacement acts as effectively as wild-type
transgenic cMyBP-C in rescuing the MYBPC3(t/t) phenotype (Sadayappan,
Osinska et al. 2006), showing the necessity of phosphorylation for normal cardiac
function.
While evidence for alterations in cMyBP-C phosphorylation as a modifier of
disease has been growing for the last decade, new insights into how cMyBP-C
phosphorylation alters sarcomere function have added to the mechanistic
understanding of sarcomere regulation. Phosphorylation of cMyBP-C has been
proposed to alter the structure of the M-domain. These findings fit nicely with
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observations regarding the hierarchal phosphorylation relationship of the major
M-domain serine residues. Phosphorylation has been proposed to cause
rearrangement of the structure of the M-domain may expose additional serine
residues

for

phosphorylation

by

kinases,

establishing

a

hierarchy

of

phosphorylation (Previs, Beck Previs et al. 2012, Weith, Sadayappan et al. 2012,
Bezold, Shaffer et al. 2013, Karsai, Kellermayer et al. 2013).
Phosphorylation of cMyBP-C has been shown to directly alter the actomyosin crossbridge cycling rate. In a series of experiments measuring the speed
of actin filament propagation along a myosin-coated surface, regions with
dephosphorylated cMyBP-C were shown to slow actin sliding velocity
significantly compared to areas with no cMyBP-C. However, additional
phosphorylation of the major serine sites in the M-domain showed step-wise
increases in actin sliding velocity, such that when cMyBP-C was maximally
phosphorylated actin sliding velocity was equal to its velocity in the absence of
cMyBP-C. These data illustrate the ability of cMyBP-C to regulate sarcomere
shortening velocities based on the level of phosphorylation. Due to the
complexity of kinase signaling that regulates the M-domain of cMyBP-C, these
interactions are still being explored (Previs, Beck Previs et al. 2012, Weith,
Sadayappan et al. 2012).
The ability of cMyBP-C to regulate cardiac function relies on several factors
that are altered in hypertrophy, such as phosphorylation. In addition to these
modifications, sarcomere occupancy of cMyBP-C has been shown to alter
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contractile kinetics, with regions lacking cMyBP-C regulating actin sliding
differently than regions with cMyBP-C (Weith, Sadayappan et al. 2012,
Witayavanitkul, Ait Mou et al. 2014). Therefore, any reduction in cMyBP-C level
or functional capacity can cause disruptions in sarcomere function. Due to the
importance of cMyBP-C content and modifications on sarcomere function, in this
study levels of cMyBP-C were carefully assessed as well as alterations in
phosphorylation levels.
In addition to regulating acto-myosin interactions by directly interacting with
those proteins, cMyBP-C has also been reported to interact with α-tropomyosin.
This interaction was first described in skeletal muscle (Yamamoto 1986) by
demonstrating that cMyBP-C could bind to actin/tropomyosin thin filaments.
Further evidence suggests that cMyBP-C can alter α-Tropomyosin function and
activate the thin filament. Structural studies of cMyBP-C have suggested that the
C0-C1 domains can interact with the low-Ca2+ α-Tropomyosin site on actin,
displacing α-tropomyosin from this blocked position and activating the thin
filament independent of cytosolic Ca2+ levels by exposing myosin binding sites on
actin (Orlova, Galkin et al. 2011, Mun, Previs et al. 2014).
Proteolytic degradation of cMyBP-C, as seen during I-R injury, causes
cleavage of the full-length 140-kDa cMyBP-C and the production of a 40-kDa N’fragment (Sadayappan, Osinska et al. 2006, Sadayappan, Gulick et al. 2009).
Calpain is a Ca2+-activated protease that regulates myofilament proteins (Gao,
Atar et al. 1997, Galvez, Diwan et al. 2007) and plays a role in myofibril
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degradation and is activated during I-R injury and myocardial stunning.
Developing data from the Sadayappan lab show that cMyBP-C is a substrate for
μ-calpain in vitro. The removal of the N’-terminal residues by a Ca2+ activated
protease raises many interesting questions, especially when taken with the
evidence that the major regulator of acto-myosin interaction is found within the
M-domain, which is also the location of the cleavage site. It may be that cleavage
of cMyBP-C may provide a short-term advantage in terms of increased
contractility, although the long-term effects of this modification may be
deleterious. Also, cleavage of the N’-terminal region of cMyBP-C may serve as a
biomarker for ischemic injury, as this fragment has been shown to be released
into the circulation (Kuster, Cardenas-Ospina et al. 2014).
In addition to regulatory modifications and proteolysis, recent studies have
begun to implicate oxidative modifications, such as glutathionylation, as playing a
role in pathological regulation of sarcomeric proteins. In a hypertensive mouse
model hypertrophy and sarcomeric dysfunction were shown to be modified by
cMyBP-C glutathionylation, and these deficits can be attenuated by restoring the
redox state of the cardiomyocyte, and reversing glutathionylation of cMyBP-C
(Jeong, Monasky et al. 2013, Patel, Wilder et al. 2013). Further studying the
detrimental effect of oxidative modifications on sarcomeric proteins has the
potential to provide novel targets to regulate myocardial function following
oxidative stress.
The necessity of cMyBP-C for cardiac development and function was
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reported by the Seidman lab in 1999, (McConnell, Jones et al. 1999) who also
showed that heterozygous (MYBPC3(+/t)) mice were phenotypically similar to WT
under basal conditions. Furthermore, the truncation mutation in MYBPC3(t/t) is a
good model to study typical MYBPC3 familial hypertrophic cardiomyopathy
mutations, as the majority of MYBPC3 mutations reported are expected to
produce a C’-terminal truncated protein product which are rarely detected in
patient tissue (Dhandapany, Sadayappan et al. 2009, van Dijk, Dooijes et al.
2009). In these MYBPC3(t/t) mice, there is no detectable cMyBP-C and
hypertrophy develops, similar to other knockout mice (Harris, Bartley et al. 2002).
This lack of protein incorporation in the sarcomere contributes to a phenotype of
hypertrophy, dilation, and increased fibrosis and necrosis in MYBPC3(t/t) mouse
hearts. These data underscore the importance of cMyBP-C for normal cardiac
function, and demonstrate that under basal conditions the heterozygote is
phenotypically normal, but they do not address whether the heterozygote exhibits
any deficits following stress.

2.3.3 Experimental Investigation of MYBPC3 Mutations in HCM
Diagnostic criteria state that HCM is a disease that causes hypertrophy in
the absence of an external stimulus (Go, Mozaffarian et al. 2013). This criterion
requires that other causes of hypertrophy must be ruled out, as the genetic basis
of familial HCM had not been elucidated until the mid-1990’s. In 1995 the
Seidman lab and the Schwartz lab both published in Nature Genetics the first
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evidence of mutant MYBPC3 genes involved in HCM, and that the pathological
mechanism may be improper splicing, leading to a truncated protein (Bonne,
Carrier et al. 1995, Watkins, Conner et al. 1995). The role of MYBPC3 in HCM is
now well established, with a common trend among identified mutations involving
improper splicing, exon skipping, frame shifts, and the introduction of a
premature stop codon. Of the over 200 identified mutations in MYBPC3
associated with inherited HCM, 70% are suggested to result in one of these
truncated proteins.
The

pace

of

MYBPC3

mutation

identification

picked

up

speed

tremendously in the first decade of the 21st century. As mutations were
discovered, the extent to which they were carried in various populations became
apparent. Many of the populations carrying familial HCM mutations result from
specific founder mutations, resulting in widespread distribution of particular
mutations. Notable among these are Dutch (Michels, Soliman et al. 2009) and
Italian (van Dijk, Dooijes et al. 2009) founder mutations, which are highly
abundant in their respective countries, and are also prevalent in the United
States due to the country’s diverse ethnic background.
Perhaps the most prevalent mutation in MYBPC3 was identified in 2003
(Waldmuller, Sakthivel et al. 2003, Dhandapany, Sadayappan et al. 2009). This
mutation is a 25 base pair deletion that results in skipping of exon 33, a frame
shift, and a novel stop codon in the 3’ untranslated region that ultimately results
in a predicted protein product missing several C’ residues. Functionally, the result
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of this mutation is likely similar to many other MYBPC3 mutations that cause
truncations or incorporation of novel C’ residues in the myosin binding domains.
These mutations are thought to remove key myosin binding residues on the C’ of
the protein, disallowing proper incorporation in the sarcomere. Although the
pathogenic mechanism of this mutation is still under investigation the impact of
this mutation is severe as it is thought to be carried by 60 million people of South
Asian descent (Kuster, Sadayappan 2014).
Homozygous carriers of most HCM-causing MYBPC3 mutations develop
severe hypertrophy at a young age and have a poor prognosis (Morita, Rehm et
al. 2008). However, heterozygous carriers typically start showing a mild
phenotype in early adulthood, and it is common for many carriers to not show
any symptoms until middle age, with some never demonstrating pathology.
Because of the late onset of these symptoms, it is difficult for carriers to know of
their condition until after their reproductive years, making the transmission of
these mutations common. In families with a history of HCM or sudden cardiac
death, it has become clinically important to screen for known or novel mutations
in order for carriers to make more informed life decisions regarding their own
health and reproductive options (Dhandapany, Sadayappan et al. 2009).
Since the identification of MYBPC3 as a cardiomyopathy-related gene,
increasing amounts of work have been done to identify the mechanisms by which
mutations exert pathology. This effort has used tissue collected from human
carriers, pedigree analysis of affected families, and mouse models carrying
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common human mutations. The result of nearly 20 years of work has established
that about 70% of MYBPC3 mutations are C’-truncations and are never detected
by Western blot in myocardial tissue samples from HCM patients (Harris, Lyons
et al. 2011). These MYBPC3 mutations are predicted to produce C’-truncated
protein products of cMyBP-C that are unable to incorporate into the sarcomere
due to the loss of key titin and myosin-binding residues (Harris, Lyons et al.
2011).
As a result, homozygous C’-truncations often result in total lack of cMyBPC, effectively acting as a null allele, not producing any cMyBP-C. Conversely,
some strains of asymptomatic heterozygous MYBPC3(+/t) mice show normal
cMyBP-C stoichiometry, (McConnell, Jones et al. 1999, McConnell, Fatkin et al.
2001)

suggesting

that

haploinsufficiency

is

singularly

responsible

for

development of the HCM phenotype under normal conditions. However, it is
unclear if asymptomatic human heterozygous mutation carriers have normal
levels of cMyBP-C, and whether reduced cMyBP-C levels observed in
symptomatic carrier myocardium is causative for the transition to a hypertrophic
phenotype, or is a result. Therefore, it is critical to determine the effect of
cardiovascular stress as a contributing factor in a haploinsufficiency mechanism
for the development of hypertrophy.
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2.3.4 Mouse models of MYBPC3 mutations
In the initial effort to determine the role of cMyBP-C in cardiac function,
numerous cMyBP-C mutation carrying mouse models have been developed.
Most of these models were originally designed to study the absence of cMyBP-C
in the homozygote; however, the heterozygous genotype is also quite interesting
as it mirrors the clinical situation often found in the human population. In the
Moss lab in 2002, a MYBPC3 knockout mouse model was generated that is
referred to in the literature as the “null” mouse (Harris, Bartley et al. 2002). This
model was designed with exons 3-10 removed, resulting in the absence of
cMyBP-C expression in the homozygous mouse. In initial reports, the
heterozygous genotype of this model does not exhibit any reported deficits, with
normal levels of cMyBP-C, despite reduced mRNA levels. However, more recent
evaluation of this heterozygous model does show a 32% decrease in cMyBP-C
levels, and mild functional impairments consistent with the early onset of HCM
(Desjardins, Chen et al. 2012).
Two MYBPC3 mutant mouse models were developed by Lucie Carrier,
one of which is a knockout mouse lacking exon 1 and 2 that results in a null allele
(Carrier, Knoll et al. 2004). This heterozygous mouse model does show a
reduction in cMyBP-C levels (25% of WT), with a reduction in MYBPC3 mRNA
(from ~80% to ~50% of WT levels from 6 to 11 months of age) and develops
symptoms of HCM at 10 to 11 months of age. The other model is a knock-in
mouse carrying a common human mutation that results in several mRNA splice
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products. This results in the expression of one potential poison polypeptide and
an overall 50% reduction in MYBPC3 mRNA which translates into a 20%
reduction of cMyBP-C in the heterozygote. Interestingly, this model does not
appear to develop HCM; however, these mice do show increased Ca2+ sensitivity
at the skinned fiber level and alterations in Ca2+ handling were observed in intact
cardiomyocytes (Vignier, Schlossarek et al. 2009).
A consistent theme found in all these models is that homozygous mutant
carriers show a severe hypertrophic or dilated phenotype, whereas the
heterozygous

models

are

more

variable

in

their

pathology,

showing

asymptomatic or mild phenotypes with the development of age-dependent HCM.
These observations parallel those made in human carriers of HCM causing
MYBPC3 mutations. The study of these various heterozygous mouse models
underscores the subtle mechanistic differences between specific MYBPC3
mutations, illustrating the complexity of the heterozygous condition in mouse
models and human patients.
The Seidman lab generated one of the first cMyBP-C null mouse models
that demonstrated the importance of cMyBP-C for integrity of sarcomeric
structure and its involvement in normal contractility of the heart (McConnell,
Jones et al. 1999, Palmer, Georgakopoulous et al. 2004, Palmer, McConnell et
al. 2004, Palmer, Noguchi et al. 2004). These mice model a human mutation
reported by the Seidman lab (Watkins, Conner et al. 1995) carrying a G to C
mutation at nucleotide 3367, causing an altered 5’ splice site and skipping of
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exon 30, resulting in a frame shift and the inclusion of novel predicted C’-terminal
amino acids. This cMyBP-C truncation mouse demonstrated that cMyBP-C is not
essential

for

development,

although

its

absence

causes

hypertrophic

cardiomyopathy. This homozygous truncation (t/t) MYBPC3(t/t) mouse model was
extensively characterized to demonstrate that lack of cMyBP-C leads to
development of ventricular dysfunction, ventricular arrhythmia and severe dilated
cardiomyopathy (McConnell, Jones et al. 1999, McConnell, Fatkin et al. 2001,
Palmer, Georgakopoulous et al. 2004, Palmer, McConnell et al. 2004, Palmer,
Noguchi et al. 2004). These studies showed that heterozygous MYBPC3(+/t) and
homozygous MYBPC3(t/t) mice are viable, but homozygous MYBPC3(t/t) mice
display progressive HF following hypertrophy and dilation (McConnell, Jones et
al. 1999, McConnell, Fatkin et al. 2001). Using MYBPC3(+/t) mice is intended to
model a situation where one MYBPC3 allele codes for a mutant cMyBP-C
peptide that cannot properly incorporate into the sarcomere, therefore
recapitulating the conditions expected in human heterozygous carriers of similar
mutations.
The initial reports on the MYBPC3(+/t) genotype showed normal ECG
intervals and sinus node, atrial, and ventricular conduction and refractory time,
and showed mild HCM only after 125 weeks of age (McConnell, Fatkin et al.
2001). The suitability for using this mouse to model human disease is supported
by the observation that human heterozygote carriers of MYBPC3 mutations also
show an age-dependent phenotype. In one large study, young human
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heterozygote carriers of a specific MYBPC3 mutation are mostly asymptomatic or
mildly symptomatic, whereas ~90% of the heterozygote carriers over 50 years of
age were mildly symptomatic (Dhandapany, Sadayappan et al. 2009).
Using this heterozygous model for the experiments detailed in this
dissertation, it is possible to determine whether decreased MYBPC3 expression
causes any detrimental effects under normal conditions, and whether
hypertrophic stress results in either a reduction of cMyBP-C or worsened
phenotype. These questions are clinically relevant due to the number of people
carrying these mutations and the relatively small amount known about the
mechanism by which these mutations exert a pathological effect.
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CHAPTER THREE
AIMS AND HYPOTHESIS

Based on the observation that human heterozygous carriers of MYBPC3
mutations have variable penetrance and are often asymptomatic until middle
age, I investigated whether haploinsufficiency of MYBPC3 predisposed carriers
to the development of HCM and HF. To accomplish this I used a mouse model
developed by McConnell et al (1999) with one functional allele of MYBPC3 and
one allele containing a truncating mutation that results in a null allele. I
hypothesize that mice with heterozygous MYBPC3 truncation mutations
(MYBPC3(+/t)) have subtle functional deficits and these mice will respond worse to
cardiac stress than WT controls. Therefore, the overall objectives of this proposal
were to 1) determine if the MYBPC3(+/t) mice, initially reported as asymptomatic,
show subtle functional deficits that may presage the development of hypertrophy;
2) demonstrate that insufficient expression of cMyBP-C contributes to the
development of HCM in MYBPC3(+/t) mice following stress.
Specific Aim 1. To assess molecular and morphological differences
between WT and heterozygous mice under basal conditions. Previous
studies established that MYBPC3(+/t) mice express normal levels of cMyBP-C and
exhibit a benign phenotype until extreme old age. Also, it has been shown that
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human heterozygous carriers of similar mutations develop cardiomyopathies in
adulthood, with delayed onset compared to homozygous carriers. Therefore, I
hypothesized that the heterozygous genotype exhibits subtle functional
impairments that facilitate the development of HCM. To test this hypothesis,
levels of cMyBP-C transcript and protein were assessed and alterations in
protein localization and phosphorylation status were evaluated. Force-pCa
measurements of skinned cardiomyocytes and echocardiography analysis
evaluated whether the heterozygous mice show any deficiencies under normal
conditions.
Specific Aim 2. To determine if the MYBPC3 heterozygous mice are more
susceptible to the development of HCM following cardiovascular stress.
Previous studies using this mouse strain have shown normal levels of cMyBP-C
under baseline conditions, whereas studies using HCM symptomatic MYBPC3
mouse models and in human HCM patients have shown a reduction in cMyBP-C
levels. I hypothesized that an increased demand for protein synthesis results in
reduced cMyBP-C levels following cardiac insult, and this reduction in cMyBP-C
exacerbates the onset of HCM. To test this hypothesis, transverse aortic
constriction was used to induce hypertrophy. Echocardiography and skinned
cardiomyocyte force measurements were used to assess function. Protein and
mRNA levels were measured to evaluate haploinsufficiency, and RNA-Seq was
performed to assess alterations in signaling pathways.

CHAPTER FOUR
CONTRACTILE DYSFUNCTION IN HETEROZYGOUS MYBPC3 MICE

4.1 Abstract
The etiology of hypertrophic cardiomyopathy (HCM) has been ascribed to
mutations in genes encoding sarcomere proteins. In particular, mutations in
MYBPC3, a gene which encodes cardiac myosin binding protein-C (cMyBP-C),
have been implicated in over one-third of HCM cases. Of these mutations, 70%
are predicted to result in C’-terminal truncated protein products which are
undetectable in tissue samples. Heterozygous carriers of these truncation
mutations exhibit varying penetrance of HCM, with symptoms often occurring
later in life. We hypothesize that heterozygous carriers of MYBPC3 mutations,
while seemingly asymptomatic, have subtle functional impairments that precede
the development of overt HCM. This study compared heterozygous (+/t) knock-in
MYBPC3 truncation mutation mice with wild-type (+/+) littermates to determine if
functional alterations occur at the whole-heart or single-cell level prior to the
onset of hypertrophy. The +/t mice show ~40% reduction in MYBPC3
transcription with no changes in cMyBP-C level, phosphorylation status, or
cardiac morphology. However, cardiomyocytes from +/t mice show significantly
decreased maximal force development at sarcomere lengths of 1.9 µm and 2.3
68
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µm. In addition, heterozygous mice show significant reductions in vivo in the
early/after (E/A) and E’/A’ ratios, indicating diastolic dysfunction. These results
suggest that seemingly asymptomatic heterozygous MYBPC3 carriers do suffer
impairments that may presage the onset of HCM.

4.2 Introduction
Protein analysis of heart tissue from symptomatic heterozygous carriers of
MYBPC3 mutations have shown reduced cMyBP-C levels compared to human
non-failing donor hearts (Moolman, Reith et al. 2000, van Dijk, Dooijes et al.
2009, Marston, Copeland et al. 2012). This observation is paralleled in certain
mouse models of MYBPC3 mutations, where symptomatic heterozygous mice
have shown a decreased amount of cMyBP-C in the heart (Carrier, Knoll et al.
2004, Vignier, Schlossarek et al. 2009, Desjardins, Chen et al. 2012, Cheng,
Wan et al. 2013). However, certain other heterozygous mouse models have
demonstrated normal cMyBP-C levels with generally asymptomatic phenotypes
(McConnell, Jones et al. 1999, Harris, Bartley et al. 2002). Therefore, it is
currently

unclear

whether

reduction

in

cMyBP-C

content

initiates

the

development of HCM via haploinsufficiency or if other less direct mechanisms
are involved in the early stages of the pathology.
The functional impairments observed in heterozygous carriers of MYBPC3
truncation mutations have been suggested to result from reduced cMyBP-C
levels (Moolman, Reith et al. 2000, van Dijk, Dooijes et al. 2009, Marston,
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Copeland et al. 2012). However, transition to symptomatic HCM with reduced
cMyBP-C levels remains poorly understood based in no small part on the
uncertainty of whether reduced cMyBP-C levels are causative for this transition
or are a result. Accordingly, this study investigated the physiological
consequences exhibited by a mouse model previously described as having
preserved cMyBP-C levels, but carrying only one functional allele of MYBPC3.
To accomplish this, a MYBPC3 truncation mutant mouse model generated
by McConnell et al. was used (McConnell, Jones et al. 1999, McConnell, Fatkin
et al. 2001, Palmer, McConnell et al. 2004). This model carries a knock-in
mutation in MYBPC3 that results in the skipping of exon 30, a frame shift, and
inclusion of a premature stop codon. As previously reported, the homozygous
(t/t) mouse has no detectable cMyBP-C, increased fibrosis, dilation of the left
ventricle, and decreased cardiac function leading to the development of heart
failure (McConnell, Jones et al. 1999, Palmer, Georgakopoulous et al. 2004,
Palmer, McConnell et al. 2004, Palmer, Noguchi et al. 2004). The original
characterization of this model focused primarily on the homozygous genotype.
However, the heterozygous mouse (+/t) was shown to be asymptomatic, with a
level of cMyBP-C equal to that of wild-type (+/+). Also, hypertrophy was not
reported in the initial characterization until the animals were over two years of
age (McConnell, Jones et al. 1999, McConnell, Fatkin et al. 2001). Information
about gene expression, myofilament performance and in vivo function were not
reported for the heterozygote. As this heterozygous mouse appears to be
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asymptomatic and maintains normal cMyBP-C levels, it is ideal for testing
whether subtle deficits in cellular and cardiac function are present in the
heterozygous mouse prior to the development of overt HCM.

4.3 Results
4.3.1 Heterozygous Express an Intermediate Level of MYBPC3 Transcript
with Preserved cMyBP-C Content
Myofilament protein fractions isolated from three months old +/+ and +/t
contained an equal amount of cMyBP-C, while no cMyBP-C was present in t/t
hearts (Figure 8A). Furthermore, quantification of cMyBP-C in whole-heart
homogenates showed that cMyBP-C levels normalized to actin are unchanged
between the +/+ and +/t groups, consistent with previous reports (Figure 8B)
(McConnell, Jones et al. 1999, Palmer, McConnell et al. 2004). In contrast to the
protein data, levels of MYBPC3 transcript measured by qPCR were significantly
reduced in the +/t group compared to +/+ (64% of +/+ levels), and t/t levels were
significantly reduced compared to +/+ and +/t (16% of +/+ levels) using primers
that recognize WT and truncated transcript (Figure 8D).
Protein levels of the pathological hypertrophy marker β-myosin heavy
chain (β-MHC) resolved by SDS-PAGE and stained with Sypro-Ruby showed no
change between +/+ and +/t, whereas the t/t hearts showed a significant
elevation in β-MHC (Figure 8C). Analysis of the transcript levels of hypertrophic
markers via qPCR showed no difference in either β-MHC (MYH7) or atrial
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natriuretic factor (NPPA) between +/+ and +/t, with a significant elevation in the t/t
mouse hearts (~6 fold increase in both MYH7 and NPPA) (Figure 8E & F).
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Figure 8. Expression of MYBPC3 and hypertrophic markers.
A, Myofilament protein fraction resolved with SDS-PAGE and stained with
Coomassie blue. B, Western blot showing levels of cMyBP-C and actin. Western
blot quantification shows no cMyBP-C present in the t/t samples and no
significant change in cMyBP-C levels between +/+ and +/t. (n=5) C, Total heart
homogenate used for analysis of myosin heavy chain isoforms (-MHC and MHC) resolved on a Hoefer format SDS-PAGE and stained with Sypro-Ruby.
The +/+ and +/t hearts show no changes in -MHC isoform levels, with t/t hearts
showing a significant increase in the hypertrophic marker -MHC. (N=11, 8, 9) D,
Relative MYBPC3 expression is reduced in +/t hearts compared to +/+ hearts,
and t/t hearts show an even further reduction in MYBPC3 expression, normalized
to GAPDH expression. E & F, Relative transcript levels of hypertrophic markers
MYH7 and NPPA are unchanged in +/+ and +/t hearts, but they show a
significant increase in the t/t hearts normalized to GAPDH expression. (N=6,7,3)
*P<0.05 vs. +/+, #P<0.05 vs. +/t. (Barefield, Kumar et al. 2014).
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4.3.2 Phosphorylation of cMyBP-C Regulates Sarcomere Function.
In order to determine whether the phosphorylation status of cMyBP-C was
altered in the +/t hearts, phosphorylation-dependent, site-specific antibodies to
pS273, pS282, and pS302 were used. Phospho-cMyBP-C levels were
normalized to total cMyBP-C (as shown in Figure 1B) and normalized to actin for
a loading control. No changes in the phosphorylation status of cMyBP-C at serine
273, 282, or 302 were detected between +/+ and +/t groups (Figure 9A).
Additionally, phosphorylation levels of cardiac troponin I (cTnI) at serine 23 and
24 showed no difference between +/+ and +/t or t/t, although a higher variability
of phospho-cTnI was observed compared to phospho-cMyBP-C (Figure 9B).
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Figure 9. Phosphorylation of cMyBP-C and cTnI.
A, Western blot analysis detecting cMyBP-C phosphorylated at serine-273, -282,
and -302. No significant change in phosphorylation of cMyBP-C was observed at
any of the phosphorylation sites between the +/+ and +/t groups. (n=5) B, The
phosphorylation status of cTnI at serine-23 and -24, as determined by Western
blot, shows no significant changes in any of the groups. (n=5) (Barefield, Kumar
et al. 2014).
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4.3.3 Heterozygous Mice do not Exhibit Gross Morphological Changes
Analysis of gross morphology and coronal sections of +/+ and +/t hearts
showed no obvious pathology, whereas t/t hearts showed dilation as previously
reported (Figure 10A & B) (McConnell, Jones et al. 1999). Heart weight to body
weight ratios showed no significant difference between +/+ (4.58 ± 0.32 mg/g
HW/BW) and +/t (4.62 ± 0.08 mg/g HW/BW) (n=4). Similarly, H&E and Trichrome
staining revealed no disparities between +/+ and +/t samples (Figure 10C & D).
Immunostaining of isolated cardiomyocytes showed doublet patterning consistent
with properly localized C-band incorporation of cMyBP-C (green) between the αactinin-stained Z-disks (red) in both the +/+ and +/t groups (Figure 10E). These
observations agree with the original characterization of this model and show that
the +/t heart appears to have proper cMyBP-C incorporation with no grossly
apparent phenotype.
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Figure 10. Gross morphology and protein incorporation.
A, Representative whole heart images and B, coronal sections show no overt
hypertrophy in the +/t hearts, whereas t/t hearts display a hypertrophic
phenotype. C, Cross-sectional H&E and D, Trichrome staining reveal deranged
muscle arrangement and fibrosis, respectively, in the t/t heart, with no notable
differences in +/+ and +/t. E, Confocal microcopy immunofluorescence of isolated
cardiomyocytes stained for cMyBP-C (Green) and α-actinin (Red). The cMyBP-C
signal shows the characteristic C-zone doublet pattern between each Z-disk,
stained for α-actinin in both +/+ and +/t cardiomyocytes. Staining of the t/t cells
reveals only minimal cMyBP-C signaling and no structural localization. (Barefield,
Kumar et al. 2014).
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4.3.4 Heterozygous Cardiomyocytes Show Reduced Force Generation
Force-pCa analysis was performed to assess disparities in myofilament
function between +/+ and +/t myocytes. Skinned myocytes showed a reduction in
maximal developed force (FMAX) at pCa 4.5 (3.16µM Ca2+) in both +/t (68.5 ± 4.1
mN/mm2 at SL 1.9; 79.2 ± 3.1 mN/mm2 at SL 2.3, P=0.007 SL 1.9, P=0.004 SL
2.3) and t/t (69.3 ± 3.3 mN/mm2 at SL 1.9; 81.1 ± 3.1 mN/mm2 at SL 2.3,
P=0.0241 SL1.9, P=0.009 SL2.3) groups compared to +/+ (82.2 ± 3.2 mN/mm 2
at SL 1.9; 95.5 ± 2.4 mN/mm2 at SL 2.3) (Figure 11A-C). We also examined
force generation at pCa 5.9 (0.13µM Ca2+) to assess tension development at low
Ca2+ concentrations. The force development of the +/+ myocytes (15.5 ± 3.0
mN/mm2 at SL 1.9; 22.8 ± 3.0 mN/mm2 at SL 2.3) was not significantly different
than +/t (12.8 ± 1.5 mN/mm2 at SL 1.9; 17.7 ± 1.8 mN/mm2 at SL 2.3), although a
significant (P=0.041) treatment effect was observed between +/+ and t/t (11.8 ±
1.3 mN/mm2 at SL 1.9; 16.1 ± 1.1 mN/mm2 at SL 2.3). Ca2+ sensitivity of force
development, expressed as pCa50, was significantly increased only in t/t hearts at
SL 2.3 µm compared to +/+ (Figure 11D). The +/+ hearts show a significant
change in pCa50 (P=0.01) with changes in sarcomere length, whereas this
change is not observed in +/t or t/t (Table 2).
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Figure 11.
Generation.

Heterozygous

Cardiomyocytes

Exhibit

Impaired

Force

A-C, Maximum development of force is significantly decreased in +/t and t/t
skinned cardiomyocytes compared to +/+ at both short (SL 1.9 µm) and long (SL
2.3 µm) sarcomere lengths. D, Relative force comparisons show a significant
decrease in Ca2+ sensitivity of force development in t/t hearts compared to +/+ at
SL 2.3 µm. No significant changes in Ca2+ sensitivity were seen between +/t and
+/+. (N=6, 7, and 7 hearts per group, with 3-4 cells averaged per heart) *P<0.05
vs. +/+, #P<0.05 vs. +/t. (Barefield, Kumar et al. 2014).
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4.3.5 MYBPC3 Heterozygous Mice Have Altered Cardiac Function in vivo
Echocardiography was performed to assess morphology, systolic, and
diastolic function. M-mode parasternal long axis echocardiography showed no
difference between +/t and +/+ in interventricular septum or posterior wall
thickness (Table 3), no dilation of the left ventricle in systole or diastole, and no
changes in relative wall thickness compared to total heart thickness (Figure
12A, C-F). The +/t mice showed a non-significant (P=0.114) trend towards
reduced % fractional shortening (27.4 ± 1.5%) compared to +/+ (32.0 ± 2.1%),
with a significant (P<0.001) reduction in fractional shortening in the t/t mice
(11.53 ± 0.79) (Figure 12B).
Additionally, M-mode derived % ejection fraction followed the same nonsignificant trend between +/+ (60.6% ± 3.0) and +/t (53.6 % ± 2.5), with a
significant (P<0.001) reduction in systolic function in the t/t group (24.9% ± 1.6).
Power Doppler measurements of left ventricular filling revealed a significant
reduction (P=0.003) in the early/after (E/A) ratio in +/t (1.74 ± 0.12) compared to
+/+ (2.58 ± 0.53) (Figure 12G). Tissue Doppler analysis of mitral valve motion
also showed a significant decrease (P=0.025) in the early movement of the
myocardium around the mitral valve (E’) compared to the tissue motion
associated with atrial contraction (A’), known as the E’/A’ ratio in the +/t mice
(1.18 ± 0.05) compared to +/+ (1.52 ± 0.15) (Figure 12H). While these diastolic
parameters showed significant impairments in +/t, other parameters, such as the
E’ and E velocities, as well as the E/E’ ratio, comparing blood flow velocity of
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early filling compared to tissue movement, were not significantly altered (Table
3). Diastolic function was not assessed in t/t mice because that group was not
available at the time diastolic parameters were measured.
In order to assess any additional whole-heart functional deficits, 2
dimensional echocardiography strain analysis was performed on B-mode longaxis images (Table 4). In both +/+ and +/t mice the left ventricle contracted
synchronously, and no difference was detected in peak % strain, or time to peak.
Furthermore, the strain rate and time to peak strain rate were unchanged.
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Figure 12. Diastolic Dysfunction in Heterozygous Hearts
A, Representative parasternal long-axis M-mode echocardiography tracings from
10- to 12-week-old +/+, +/t, and t/t mouse hearts. B, Percent of left ventricular
fractional shortening shows that +/t hearts trend towards reduced pump function
compared to +/+, whereas t/t hearts show a significant deficit compared to both
+/+ and +/t groups. C & D, Left ventricular internal diameter (LVID) at peak
systole and diastole shows significant dilation in the t/t hearts with no changes
between +/+ and +/t. E & F, relative wall thickness (anterior + posterior wall / total
heart thickness) at peak systole and diastole shows no change between +/t and
+/+, whereas the wall-to-heart ratio is reduced in t/t. G & H, Representative
power and tissue Doppler images depicting the early (E) and late (A) blood filling
of the left ventricle and mitral valve motion. E/A and E’/A’ ratios were significantly
reduced in +/t hearts compared to +/+, with t/t hearts showing a significant deficit
compared to both groups. (N= 7, 10, 9) *P<0.05 vs. +/+, #P<0.05 vs. +/t.
(Barefield, Kumar et al. 2014).
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+/+

+/t

t/t

ΔFMAX(mN/mm2)

13.36 ± 1.51

12.52 ± 2.33

11.72 ± 0.96

ΔpCa50

0.084 ± 0.012

0.058 ± 0.006

0.046 ± 0.008
*

SL 1.9
FMAX(mN/mm2)

82.2 ± 3.2

68.5 ± 4.1 *

69.3 ± 3.3 *

pCa50

5.57 ± 0.03

5.58 ± 0.02

5.53 ± 0.02

nH

1.91 ± 0.09

2.15 ± 0.12

2.10 ± 0.04

SL 2.3
FMAX(mN/mm2)

95.5 ± 2.4

79.2 ± 3.1 *

81.0 ± 3.1 *

pCa50

5.66 ± 0.02

5.64 ± 0.01

5.58 ± 0.02 *

nH

2.02 ± 0.05

2.29 ± 0.10

2.07 ± 0.08

Table 2. Summary of force-pCa analysis of skinned cardiomyocytes.
Significant reductions in FMAX are observed in +/t and t/t compared to +/+ skinned
cardiomyocytes. Significant alteration in calcium sensitivity of force development
was only detected in the t/t skinned cardiomyocytes at SL 2.3 µm. No significant
changes in Hill coefficient or length-dependent activation were observed. (n=3
+/+ hearts, 4 +/t and t/t hearts per group, with 4 cells averaged per heart)
*P<0.05 vs. +/+, #P<0.05 vs. +/t. (Barefield, Kumar et al. 2014).
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+/+

+/t

t/t

n

7

10

9

FS (%)

32.02 ± 2.08

27.36 ± 1.48

11.53 ± 0.79 * #

E (mm/s)

784 ± 36

768 ± 38

-

E/A

2.58 ± 0.43

1.74 ± 0.12 *

-

E' (mm/s)

-22.8 ± 3.2

-22.7 ± 5.7

-

E'/A'

1.52 ± 0.15

1.18 ± 0.05 *

-

E/E'

-35.3 ± 7.2

-35.8 ± 10.0

-

IVS;d (mm)

0.98 ± 0.05

1.05 ± 0.05

1.09 ± 0.05

IVS;s (mm)

1.40 ± 0.05

1.44 ± 0.07

1.27 ± 0.07

LVID;d (mm)

3.75 ± 0.1

3.87 ± 0.11

4.92 ± 0.16 * #

LVID;s (mm)

2.55 ± 0.13

2.82 ± 0.13

4.36 ± 0.17 * #

LVPW;d (mm)

1.00 ± 0.06

1.03 ± 0.05

1.10 ± 0.07

LVPW;s (mm)

1.35 ± 0.07

1.25 ± 0.06

1.23 ± 0.08

Table 3. Summary of Echocardiography Results.
Significant reduction in fractional shortening (FS) was observed between t/t and
+/+. E/A and E’/A’ ratios were significantly reduced in +/t compared to +/+.
*P<0.05 vs. +/+, #P<0.05 vs. +/t. (Barefield, Kumar et al. 2014).
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Table 4. Summary of Echocardiography Strain Analysis.
Radial and longitudinal strain peak % and strain rate show no significant
differences between +/+ and +/t hearts. Also, time to peak strain and strain rate
showed no significant alterations between groups. N=6
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4.4 Discussion
This study aimed to detect functional deficits in a MYBPC3 heterozygous
mutant mouse with preserved cMyBP-C levels. While this heterozygous model
has normal cMyBP-C levels, proper protein incorporation, and normal
morphology, the results of these experiments demonstrate that functional deficits
do exist at the whole-heart and single myocyte levels. Here we show a 36%
decrease in MYBPC3 transcription in the heterozygote, while cMyBP-C protein
levels remain normal. The preservation of cMyBP-C level in the heterozygote
could be explained by reduced myofilament degradation or a longer half-life of
cMyBP-C in the sarcomere compared to normal turnover levels in a WT heart.
This suggests that WT levels of transcript are in excess under normal conditions,
or the heterozygote maintains cMyBP-C levels by other compensatory
mechanisms, such as reduced cMyBP-C turnover. However, in spite of proper
cMyBP-C stoichiometry, maximal force development is reduced in heterozygous
myocytes, indicating that these mice have impairments in contractility.
In addition to these deficits, the heterozygous mice demonstrate a trend
towards reduced fractional shortening, which is consistently measured on the
low-normal side, even in our FVB/N wild-type mice, as well as significantly
reduced E/A and E’/A’ ratios, indicating the development of diastolic dysfunction.
On the other hand, force development in skinned myocytes did not show any
significant difference at diastolic calcium levels, leaving the cause of diastolic
dysfunction unclear. The myofilament abnormalities and alterations in organ
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function do not appear to manifest morphologically, as the heterozygote does not
show any signs of hypertrophy at the whole organ level. Nor does the
heterozygote display an increase in levels of hypertrophic markers. These
findings suggest that seemingly asymptomatic heterozygous MYBPC3 mutant
carriers do have functional impairments, which may cause the development of
HCM with increased age or when subjected to additional cardiac stress.
The mechanism by which heterozygous truncation mutations of MYBPC3
initiate the development of HCM is unclear. Human carriers of these mutations
exhibit variable disease penetrance, often with no expression of the mutant
protein (Rottbauer, Gautel et al. 1997). Heterozygous carriers of various
MYBPC3 mutations are typically asymptomatic until adulthood and often develop
a mild phenotype compared to homozygous MYBPC3 mutant carriers (Charron,
Dubourg et al. 1998, Niimura, Bachinski et al. 1998, Moolman, Reith et al. 2000,
Dhandapany, Sadayappan et al. 2009). The variable penetrance of these
mutations is evident in pedigree analysis of mutation-carrying families, where the
same mutation can result in asymptomatic or symptomatic phenotypes (Charron,
Dubourg et al. 1998, Niimura, Bachinski et al. 1998, Moolman, Reith et al. 2000,
Dhandapany, Sadayappan et al. 2009).
The role that MYBPC3 haploinsufficiency plays in these cases is also
unclear. In symptomatic heterozygous mutation carriers, a reduced level of
cMyBP-C has been identified (Moolman, Reith et al. 2000, Marston, Copeland et
al. 2009, van Dijk, Dooijes et al. 2009). This reduction in protein has been linked
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to a reduction in force development, although this may be attributed to the HCM
phenotype, as these alterations are also observed in HCM patients with nonMYBPC3 mutations and normal cMyBP-C levels (van Dijk, Paalberends et al.
2012, Sequeira, Wijnker et al. 2013). However, since samples from
asymptomatic mutation carriers are unavailable, it is unclear whether reduction of
cMyBP-C initiates the development of HCM or merely accompanies it, as the
result of an unknown primary effect. A better understanding of the early changes
in these pathways would provide additional opportunity for diagnosis and
intervention (Germans, Russel et al. 2010).
Several cMyBP-C knockout mouse models have been developed over the
last 15 years. The model developed by the Seidman laboratory in 1999, which
was used for this work, was generated with a knock-in mutation resulting in a
gene encoding a predicted truncated protein, which is undetectable in the heart.
Heterozygous mice with this mutation do not show a hypertrophic phenotype,
whereas the homozygous mouse develops dilated cardiomyopathy, decreased
cardiac function, and a reduction in force development (McConnell, Jones et al.
1999, McConnell, Fatkin et al. 2001, Palmer, Georgakopoulous et al. 2004,
Palmer, McConnell et al. 2004, Palmer, Noguchi et al. 2004). The MYBPC3
knockout “null” mouse model was generated in the Moss laboratory in 2002. This
model has exons 3-10 removed, resulting in the absence of cMyBP-C expression
in the homozygous mouse (Harris, Bartley et al. 2002). In initial reports, the
heterozygous genotype of this model does not exhibit any reported deficits, with
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normal levels of cMyBP-C, despite reduced mRNA levels (Harris, Bartley et al.
2002). However, more recent evaluation of this heterozygous model does show a
32% decrease in cMyBP-C levels, as well as mild functional impairments
consistent with the onset of HCM (Cheng, Wan et al. 2013), (Desjardins, Chen et
al. 2012).
Two MYBPC3 mutant mouse models were developed in the Carrier lab
(Carrier, Knoll et al. 2004, Vignier, Schlossarek et al. 2009), one of which is a
knockout mouse lacking exon 1 and 2, resulting in a null allele (Carrier, Knoll et
al. 2004). In contrast to the Seidman model, this heterozygous mouse model
does show a reduction in cMyBP-C levels (25% of WT), with a reduction in
MYBPC3 mRNA (from ~80% to ~50% of WT levels from 6 to 11 months of age),
and develops HCM symptoms at 10-11 months of age (Carrier, Knoll et al. 2004).
The other model is a knock-in mouse carrying a common human mutation that
results in several mRNA splice products. This causes the expression of one
potential poison polypeptide and an overall 50% reduction in mRNA, in turn
resulting in a 20% reduction of cMyBP-C in the heterozygote (Vignier,
Schlossarek et al. 2009). While this model does not appear to develop HCM,
these mice do show increased calcium sensitivity at the skinned fiber level, and
alterations in calcium handling were observed in intact cardiomyocytes (Fraysse,
Weinberger et al. 2012).
A consistent theme found in all these models is that homozygous mutant
carriers show a severe dilated or eccentric hypertrophy phenotype, whereas the
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heterozygous models are more variable in their pathology, typically showing no
hypertrophy or mild hypertrophy, with the development of age-dependent HCM.
These observations parallel those made in human carriers of MYBPC3 mutations
that are linked to HCM. The study of these various heterozygous mouse models
underscores the subtle mechanistic differences among specific MYBPC3
mutations, illustrating the complexity of the heterozygous condition in mouse
models and human patients. The mechanism that drives the development of
dysfunction

in

heterozygous

mutant

mice

is

currently

unclear.

A

haploinsufficiency model suggests that reduction of cMyBP-C levels from
insufficient expression from one wild-type allele causes the initial insult for the
development of HCM. The poison polypeptide model proposes that mutant
MYBPC3 genes express a protein that is potentially unable to incorporate
properly into the sarcomere, causing disruption of cellular processes. However,
in cases where cMyBP-C levels are preserved and little mutant MYBPC3
transcript is present, other mechanisms may be involved. For example, it has
been suggested that chronic expression of mutant transcript or misfolded protein
may overwhelm and impair the ubiquitin-proteasome system or the nonsensemediated mRNA decay pathway over an individual’s lifetime and may account for
the late onset of hypertrophy (Vignier, Schlossarek et al. 2009, Schlossarek,
Englmann et al. 2012, Schlossarek, Schuermann et al. 2012).
In this study, it was observed that heterozygous truncation in mice results
in reduced mRNA levels, a full cMyBP-C complement, and only minor functional
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disparities. Thus, even in non-hypertrophic carriers, some perturbations may be
occurring. The identity of these alterations and whether they are compensatory
processes or the result of decomposition remain to be clarified. Elucidating the
mechanism by which lower levels of gene expression can lead to a disease
phenotype, while protein levels are maintained, is an interesting problem. One
line of inquiry into this problem might examine the effect of MYBPC3 gene
dosage relative to normal cMyBP-C protein turnover in the sarcomere such that
lower gene expression could lead to an increased half-life of cMyBP-C. Another
potential explanation previously reported implicates expression of mutant RNA or
protein as a mechanism, but not through the traditional poison polypeptide model
(Vignier, Schlossarek et al. 2009, Schlossarek, Englmann et al. 2012,
Schlossarek, Schuermann et al. 2012). This hypothesis asserts that an increased
need to degrade aberrant mRNA via nonsense-mediated decay, or misfolded
protein via proteasome or autophagic pathways, exerts a stress on the
cardiomyocytes and prevents normal cellular housekeeping, leading to
dysfunction. It is also not absolutely clear if the truncated gene is able to express
small amounts of mutant cMyBP-C, which could result in a functional impairment
of the sarcomere.
As the results of this study indicate that the this heterozygous mouse is
already functionally compromised, it would be beneficial to determine if these
animals have an increased risk for hypertrophy following cardiovascular stress,
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as this may provide direct insight into the development of HCM and heart failure
in human carriers of heterozygous MYBPC3 mutations.

CHAPTER FIVE
HAPLOINSUFFICIENCY OF MYBPC3 IN THE DEVELOPMENT OF
HYPERTROPHIC CARDIOMYOPATHY

5.1 Abstract
Mutations in MYBPC3, encoding for cMyBP-C, account for nearly 40% of
identified HCM causing mutations and often results in an absence of protein (i.e.
haploinsufficiency). Heterozygous human carriers and mouse models have
variable disease penetrance and late onset of HCM. Our objective was to
determine if heterozygous MYBPC3 mutant carriers with preserved cMyBP-C
levels under normal conditions are at a greater risk for HCM after cardiac stress.
To investigate this question transverse aortic constriction or sham surgery was
performed on 10-12 week old wild-type (WT) and MYBPC3 heterozygous (Het)
mice, followed by four or 12 weeks to allow the development of hypertrophy.
Heart weight/body weight ratios were significantly elevated 12 weeks post-TAC in
WT and Het compared to sham controls, with Het TAC hearts showing
significantly more hypertrophy than WT TAC. Echocardiography derived ejection
fraction was significantly decreased in WT and Het mice post-TAC compared to
sham controls. Force-pCa measurements on skinned myocytes showed
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significant reduction in maximal force generation in both TAC groups, and also
showed significant disparities in Het sham in force development and Ca2+
sensitivity. Levels of cMyBP-C assessed by Western blot show significant
reductions at 4 weeks in both Het groups, which are no longer seen at 12 weeks.
These observations suggest that haploinsufficiency of MYBPC3 does hasten the
pathogenesis of HCM after cardiac insult. Further exploration of how
heterozygous mutations in MYBPC3 predispose the heart to the development of
maladaptive hypertrophic remodeling could provide novel therapeutic targets for
the large number of human carriers of similar mutations.

5.2 Introduction
Recent reports have shown that cMyBP-C protein levels are decreased in
symptomatic heterozygous carriers of several MYBPC3 truncating mutations
(van Dijk, Dooijes et al. 2009, Copeland, Sadayappan et al. 2010). For obvious
reasons examining cMyBP-C levels in the hearts of asymptomatic mutation
carriers is nearly impossible, and therefore it remains unclear if the development
of HCM occurs concomitantly with a reduction in cMyBP-C levels, or whether
either event is causative for the other. Several mouse models of MYBPC3
truncation mutations currently exist and in most of these models the
heterozygous genotype has been shown to be mildly symptomatic with reduced
cMyBP-C levels (Fraysse, Weinberger et al. 2012, Cheng, Wan et al. 2013).
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However, one heterozygous model has been shown to have normal
cMyBP-C stoichiometry (McConnell, Jones et al. 1999). This model was initially
thought to be asymptomatic but recent work from our group shows that despite
normal levels of cMyBP-C, subtle functional deficits begin to manifest prior to the
development of HCM (Barefield, Kumar et al. 2014). Using these mice I tested
the hypothesis that heterozygous carriers are more susceptible to pressureoverload induced cardiovascular stress and are predisposed to the development
of HCM. I also tested whether this stress causes haploinsufficiency in the
heterozygous state, resulting in decreased cMyBP-C levels and additional
dysfunction.

5.3 Results
5.3.1 Increased Hypertrophy in Heterozygous Mice Following TAC
In order to initiate hypertrophic remodeling, 10-12 week old WT and Het
mice underwent a transverse aortic constriction (TAC) pressure-overload
procedure or a sham surgery used as a control. The success of the TAC surgery
was confirmed by assessing transverse aortic blood flow velocities at four and 12
weeks. Sham WT and Het mice show no alterations in this parameter at either
four or 12 weeks, with velocities consistent with naïve mice. WT and Het TAC
groups show a significant increase in aortic blood flow velocity compared to
genotype controls at both four and 12 weeks. Furthermore, the aortic blood flow
velocity was not significantly altered between WT and Het TAC groups,
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suggesting that both groups received an equal amount of aortic constriction
(Figure 13). As an additional verification, this parameter was measured over the
12 week time course of the study. During this time none of the groups showed
significant differences in blood flow velocity between the four and 12 week time
point, confirming that the TAC suture remained tightly in place for the duration of
the experiment.
Cardiac hypertrophy was assessed by measuring the heart weight:
body weight ratio which showed significant increases in both WT and Het postTAC at both four and 12 weeks compared to sham controls (Figure 14). The Het
TAC hearts did not show a significant difference compared to WT TAC at 4
weeks, but did show a significant increase compared to WT following at 12
weeks post-TAC. As an additional measure of hypertrophy, analysis of the
relative percentage of α and β-MHC revealed a significant increase in the
hypertrophic marker β-MHC in the WT and Het hearts four and 12 weeks postTAC compared to their respective sham controls. However, levels of β-MHC
were not altered between WT and Het TAC (Figure 14).
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Figure 13. Hypertrophic Remodeling following TAC.
Transverse aortic blood flow velocity is significantly increased in both WT and
Het TAC groups, and to the same extent, establishing the severity of the TAC
procedure was similar and remained constant between four and 12 weeks.
*P<0.05 vs. Sham N= 5-13
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Figure 14. Het Mice Show Greater Hypertrophic Remodeling Following TAC
Hypertrophy measured by HW:BW and the Sypro stained gels of separated
myosin isoforms to detect the hypertrophic marker β-MHC showed both TAC
groups underwent hypertrophic remodeling. These effects were similar at four
weeks, however at 12 weeks the Het TAC showed significantly greater
hypertrophy than the WT TAC (B). N= 5-13 (A), 5 (B) *P<0.05 vs. Sham, #P<0.05
vs. WT.
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5.3.2 Gene Expression Profile Shows Hypertrophy Post-TAC
MYBPC3 gene expression was measured with qPCR. Samples from Het
hearts from both sham and TAC groups showed a significant reduction in
MYBPC3 expression compared to wild-type sham and TAC controls. This was
observed at both four and 12 weeks post-surgery. The reductions in MYBPC3
transcript were similar to the 37% reduction observed in the Het naïve hearts
compared to WT naïve hearts as previously reported (Barefield, Kumar et al.
2014). This suggests that there is no significant increase in MYBPC3 gene
expression in the Het hearts during hypertrophic remodeling at four and 12
weeks (Figure 15).
Transcript levels of hypertrophic markers NPPA (atrial natriuretic factor)
and MYH7 showed significant increase in both WT and Het post-TAC at four and
12 weeks. The levels of these hypertrophic markers measured with qPCR
confirmed the results from RNA-Seq, with good agreement between these two
methods (Figure 15). Also, while there were no differences reported in the levels
of MYH7 and NPPA between WT and Het TAC at 12 weeks from qPCR analysis,
NPPA levels assessed by RNA-Seq showed significant increase in Het TAC
compared to WT TAC (Figure 15).
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Figure 15. Gene Expression Profiles of MYBPC3 and Hypertrophic Markers.
Expression levels of MYBPC3, NPPA, and MYH7 were quantified by RNA-Seq
and qPCR. Significant reduction in MYBPC3 transcript levels were observed in
both Het samples, consistent with reduced transcript observed at baseline.
Hypertrophic markers show significant increase in both TAC groups. (N=4)
*P<0.05 vs. Sham, #P<0.05 vs. WT, †P<0.001 false discovery rate test.
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5.3.3 Decreased cMyBP-C Content in Heterozygous Sarcomeres
Protein levels of cMyBP-C assessed by western blot showed a significant
reduction in both Het sham and Het TAC compared to WT controls (~30% of WT)
four weeks post-surgery. However, by 12 weeks post-surgery no significant
changes between WT and Het samples were detectable in either Sham or TAC
treatments, although Het TAC mice showed a non-significant reduction in
cMyBP-C compared to WT TAC (Figure 16).
Phosphorylation of myofilament proteins plays a role in regulation of
cardiac function. Phospho-specific antibodies were used to assess the
phosphorylation status of cMyBP-C on serine 273, 282, and 302, as well as the
phosphorylation status of cTnI on serines 23/24. Four weeks following TAC, WT
and Het hearts showed a significant interaction effect (2-way ANOVA reported a
significant difference between the response of the two genotypes to the two
treatments) in the increase in cMyBP-C phosphorylation at all three serine sites
(Figure 17). Surprisingly, the Het sham hearts also showed a significant increase
in phosphorylation at Ser-273 and 282 compared to WT sham, which differs from
the equal phospho-cMyBP-C levels observed under baseline conditions between
WT and Het. This finding complicates the analysis by statistical methods. By 12
weeks following surgery, phosphorylation was significantly reduced at Ser-273 in
both WT and Het TAC hearts compared to sham, with no significant differences
observed in Ser-282 in any group, and a significantly increased level of
phosphorylation at Ser-302 in Het TAC compared to WT TAC. Also, by 12 weeks
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the several-fold increase observed at four weeks had decreased to levels similar
to WT Sham (Figure 17).
In addition to alterations in cMyBP-C phosphorylation, levels of
phosphorylation of cTnI on Ser-23/24 were assessed at four and 12 weeks.
Myofilament enriched protein fractions showed a significant increase in phosphocTnI in both WT and Het TAC mice at four weeks compared to their respective
sham

controls,

consistent

with

expected

hypertrophic

signaling

and

hyperphosphorylation of cMyBP-C. However, the elevation in phosphorylated
cMyBP-C residues in Het Sham was not observed in cTnI at four weeks. Twelve
weeks following TAC the large fold increase in cTnI phosphorylation had
subsided, returning closer to WT Sham levels. However, Het Sham showed
significantly higher levels of phosphor-cTnI compared to WT Sham. There also
was a significant interaction effect detected by two-way ANOVA, which describes
the non-significant trend towards increased phosphorylation in both TAC groups
at 12 weeks (Figure 18).
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Figure 16. Het Hearts Show Reduced cMyBP-C.
Western blot analysis reveals significant reduction in cMyBP-C content in both
Sham and TAC Het hearts compared to WT at four weeks. No alterations were
observed 12 weeks following surgery. (N=4-6) *P<0.05 vs. Sham, #P<0.05 vs.
WT.
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Figure 17. Phosphorylation Status of cMyBP-C.
Phospho-cMyBP-C, normalized to total cMyBP-C showed increased trends at
four weeks, with a notabe increase in Het Sham as well. Levels of phosphocMyBP-C were reduced at 12 weeks at Ser 273, consistent with hypophosphorylation reported during the development of HF. Significant interaction
effects were noticed in Ser-273 and S-282 phosphorylation at four weeks. (N=46) *P<0.05 vs. Sham, #P<0.05 vs. WT.
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Figure 18. Phosphorylation of cTnI Ser-23/24.
Significant elevation in cTnI phosphorylation was observed in both TAC groups at
4 weeks. Phosphorylation of cTnI at 12 weeks shows reduced phosphorylation
levels with significant elevation in Het Sham. Significant interaction effects were
reported at 12 weeks. (N=4-6) *P<0.05 vs. Sham, #P<0.05 vs. WT.
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5.3.4 Reduced Contractility in Het Cardiomyocytes
In order to assess contractile performance at the level of the
cardiomyocyte, force-pCa analysis was performed. Skinned cardiomyocytes from
Het sham animals four weeks post-surgery showed a significantly reduced
maximal force generation at saturating Ca2+ concentrations at both short (Figure
19) and long SL (Figure 20). This observation is consistent with the reduction in
maximal force development observed in Het Naïve mice (Figure 11). The WT
and Het TAC mice also show a reduction in maximal force generation, although
this change is statistically confounded by interaction effects of genotype and
treatment (Figure 19, 20). At 12 weeks post-surgery Het sham cardiomyocytes
continue to exhibit a significantly decreased force generation compared to WT
sham, but only at short sarcomere length. At 12 weeks both WT and Het TAC
show a significantly reduced maximal force generation compared to sham
controls, indicating a loss of contractility at this time point which was not evident
at four weeks. Also, a significant genotype main effect was observed by 2-way
ANOVA showing significant reduction in maximal force generation in the Het
genotype compared to WT at long sarcomere length at 12 weeks.
In contrast to the trend that Het cardiomyocytes generate less force at
saturating Ca2+ levels, at diastolic Ca2+ levels (pCa 5.75) Het myocytes four
weeks post-TAC have a significantly elevated development of force at SL 1.9 vs.
WT TAC (22.1 ± 2.2 mN/mm2 vs. 15.1 ± 0.9 mN/mm2) (Table 5). This effect at
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pCa 5.75 failed to reach significance at SL 2.3, and was not significantly altered
at either sarcomere length at 12 weeks.
Length dependent increase in force development (ΔFMAX) was significantly
attenuated in the Het TAC cardiomyocytes compared to WT TAC. There was
also a significant genotype main effect by 2-way ANOVA showing a reduction in
ΔFMAX in the heterozygous genotype compared to WT at four weeks (Figure 22).
In cardiomyocytes 12 weeks following surgery a significantly reduced FMAX was
observed in both WT and Het TAC groups at long and short SL. Significant
reduction in force observed in Het Sham cardiomyocytes was still observed at
short SL compared to WT sham, with this effect not reaching significance at long
SL. No changes in ΔFMAX were observed in any of the groups at 12 weeks.
Comparing force generation at SL 1.9 there was a significant reduction in
force in both TAC groups from four weeks to 12 weeks. At long sarcomere
lengths there was a reduction in force generation over time in WT TAC cells,
although this time-course was not observed in Het TAC. Furthermore, there was
an increase in force generation capability in Het Sham between four and 12
weeks. Changes in ΔFMAX between four and 12 weeks show restoration of
length-dependent increase in force development observed in both Het groups at
12 weeks from the deficits observed at four weeks.
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Figure 19. Force Deficits in Het and TAC Cardiomyocytes at SL1.9.
Force pCa tracings at SL 1.9 for four week and 12 week groups show
significantly depressed maximal force in Het sham, as well as reduced force in
TAC hearts at 12 weeks. (N=4-6 Hearts, 3 Cells/Heart) * = p<0.05 v. Sham
control, # = p<0.05 v. WT control.
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Figure 20. Force Deficits in Het and TAC Cardiomyocytes at SL2.3.
Force pCa tracings at SL 2.3 for four week and 12 week groups show
significantly depressed maximal force in Het sham, as well as reduced force in
TAC hearts at 12 weeks. (N=4-6 Hearts, 3 Cells/Heart) * = p<0.05 v. Sham
control, # = p<0.05 v. WT control.
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Figure 21. Deficits in Length-Dependent Increase in Force Development
in Heterozygous Cardiomyocytes.
Force pCa tracings at SL 1.9 and SL2.3 for four week and 12 week groups.
Graphs depict change in maximal force generation following stretch. At four
weeks a significant genotype main effect was observed by 2-way ANOVA. (N=46 Hearts, 3 Cells/Heart) * = p<0.05 v. Sham control, # = p<0.05 v. WT control.
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Alterations in force development can be explained by changes in
myofilament Ca2+ sensitivity of force development. At four weeks post-surgery
increased Ca2+ sensitivity was observed in the cardiomyocytes from both TAC
groups compared to their respective sham controls at SL 1.9 and 2.3. Both Het
groups also showed a significant increase in Ca2+ sensitivity compared to WT
sham and TAC controls (Fig 22). The length-dependent change in pCa50 was
significantly blunted in Het sham compared to WT, and a significant genotype
main-effect was also observed.
At 12 weeks following surgery a significant genotype main-effect reduction
in Ca2+ sensitivity was observed in Het cardiomyocytes at SL 1.9. At SL 2.3 both
WT and Het cardiomyocytes were significantly less sensitive to Ca2+ compared to
sham controls. A significant genotype main effect was observed in ΔpCa 50, with
Het cardiomyocytes showing impaired stretch mediated increase in Ca2+
sensitivity.
Longitudinal comparisons show that at SL 1.9 WT sham cardiomyocytes
became more sensitive to Ca2+ between four and 12 weeks, whereas Het sham
had no alterations over time. Hey Sham cardiomyocytes also exhibited a
significantly attenuated increase in Ca2+ sensitivity compared to WT sham. While
WT TAC did not show any time-dependent changes at SL 1.9, Het TAC became
less sensitive to Ca2+ from four to 12 weeks, and was less sensitive than either
Het sham or WT TAC cardiomyocytes. A similar trend was observed at SL 2.3 for
these parameters. Interestingly, a significant genotype effect was observed in the
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change in ΔpCa50 between four and 12 weeks in the Het genotype which
showed an increase in length-dependent Ca2+ sensitization effect. This suggests
that at 12 weeks Het cardiomyocytes recovered a significant amount of lengthdependent Ca2+ sensitivity.
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Figure 22. Calcium Sensitivity of Force Development 4 and 12 Weeks
Post-TAC.
Calcium sensitivity of force development reported in at SL 1.9, 2.3 and ΔpCa50)
for four week (Left Column), and 12 week (right column). (N=4-6 Hearts, 3
Cells/Heart) * = p<0.05 v. Sham control, # = p<0.05 v. WT control, and † =
p<0.05 in single group between 4 and 12 weeks.
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Table 5. Summary of TAC and Sham Force-pCa Experiments
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5.3.5 Reduced Systolic Function in Heterozygous Hearts Post-TAC
In vivo cardiac function was assessed via echocardiography four and 12
weeks post-TAC. Systolic function measured by ejection fraction showed
significant reduction in both WT and Het TAC mice compared to sham controls at
both four and 12 week time points. Also, Het TAC mice showed a significant
reduction in ejection fraction compared to WT TAC, which was also observed at
both time points (Figure 23). The diastolic functional parameter of the E/A ratio
showed no significant changes between groups at four weeks, although by 12
weeks both TAC groups showed a significantly increased E/A ratio. E’/A’ ratio
showed an elevation in both TAC groups at four and 12 weeks (Figure 23). This
suggests that left atrial and pulmonary pressures are higher in the TAC groups,
causing increased early filling.
Septum thickness was significantly increased in both TAC groups at
peak diastole at four and 12 weeks compared to sham controls. A significant
interaction effect of treatment and genotype was observed in systolic and
diastolic septal thickness parameters at both time points, meaning that genotype
had opposite effects between both treatments, making statistical analysis difficult.
LV posterior wall thickness was also significantly increased after TAC in diastole
in both four and 12 week groups, with a significant increase in thickness
occurring at peak systole in both TAC groups at four weeks but not at 12 weeks
(Figure 24). At four weeks peak systolic LVID was significantly larger in the TAC
groups; with the peak diastolic LVID not altered suggesting normal chamber
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filling with decreased contractility, which is reflected in the ejection fraction
(Table 6). Oppositely, diastolic internal diameter was significantly increased in
both TAC hearts at 12 weeks, suggesting dilation (Table 7).
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Figure 23. Reduced Systolic Function in Heterozygous Hearts Post-TAC.
Increased hypertrophy of the septum and posterior wall was observed in both WT
and Het TAC, with increased chamber internal diameter at peak systole. TAC
hearts show a significant reduction in function, with Het TAC showing reduced
EF and FS compared to WT. The E’/A’ ratio shows alterations in the TAC groups
compared to sham. (N=5-13) *P<0.05 vs. Sham, #P<0.05 vs. WT.
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Figure 24. Increased LV Wall Thickness Post-TAC.
Echocardiography measurements of ventricle wall thickness at four and 12
weeks show hypertrophied posterior wall (LVPW) and septum (IVS) thicknesses.
The differences in diastolic and systolic IVS measurements are likely due to the
significant interaction effects from two-way ANOVA. (N=5-13) *P<0.05 vs. Sham,
#P<0.05 vs. WT.
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Table 6. Summary of Four Week Echocardiography Data.
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Table 7. Summary of 12 Week Echocardiography Data.
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5.3.6 Alterations in Gene Expression in Heterozygous Hearts.
RNA-Seq analysis revealed differential gene expression patterns in the
four groups. Genes were included in analysis if the copy number detected
reached significance following a false discovery rate test (P<0.001) and had a
fold change of 1.5 fold increase or 0.6 fold decrease. Pathway analysis was
performed using NCBI’s DAVID bioinformatics resource. A suite of 386 genes
were co-regulated in both WT and Het TAC compared to their sham controls that
contained numerous hypertrophic pathway-related genes as expected.
The initial purpose of RNA-Seq analysis was to evaluate in the ubiquitinproteasome or nonsense-mediated RNA degradation pathways were altered due
to the expression of the truncated MYBPC3 allele, as those pathways have been
hypothesized to potentially contribute to dysfunction. However, Het expression
patterns showed no significant changes in genes from these pathways in either
sham or TAC treatments, suggesting that if these pathways are altered in
disease, they are modified post-translationally.
The expression profile of Het sham samples compared to WT sham
samples revealed 20 genes to be up-regulated and 23 down-regulated (Figure
25, Table 8). The genes that were differentially regulated had various functions,
and no specific pathway was determined to be overly affected by these changes.
Some specific genes that were altered in Het sham compared to WT sham
included an up-regulation of calcipressin-1 (1.5 fold-increased in Het sham vs.
WT sham, and 1.7 fold-increased in Het TAC vs. WT TAC), which was also
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significantly up-regulated in Het TAC compared to WT TAC and a similar downregulation of atrial myosin regulatory light chain. Calcipressin-1 has antihypertrophic effects by negatively regulating calcineurin signaling.
Comparison of Het TAC gene expression with WT TAC yielded 43 upregulated and 20 down-regulated genes (Figure 26, Table 9 and 10) that were
significantly changed compared to WT TAC. Some of these genes clustered into
specific pathways related to skeletal muscle tissue development (2-fold increase
in follistatin-related precursor), immune response (up-regulation of cytokine
receptors), and fibrotic pathways (up-regulation of keratin and fibroblast growth
factors). The hypertrophic marker NPPA was significantly up-regulated in Het
TAC compared to WT TAC, consistent with qPCR data discussed previously.
Also, several pathways were significantly enriched with genes down-regulated in
Het TAC compared to WT TAC including reduction in pathways promoting
transcription, and reduction in cell signaling pathways (0.4 fold expression in
TNF, 0.3-fold expression in ATF-3, and 0.2-fold expression of Fos in Het vs. WT
TAC). Furthermore, examining the changes between Het sham and WT sham
transcript shows several altered extracellular matrix remodeling genes such as
thrombospondin-1 and a disintigrin and metalloprotease-like extracellular
protease. In order to confirm the results on the RNA-Seq data, qPCR was used
to measure levels of genes identified by RNA-Seq with high, medium, and low
levels of expression (Figure 27).
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In addition to comparing total levels of gene expression between groups,
identification of RNA splice variants is also possible with this technique. RNASeq data was consistent with qPCR data from both four and 12 weeks, as well as
from baseline samples and further confirmed that Het hearts express only ~60%
as much MYBPC3 transcript as WT (Figure 14). From this reduced amount of
total transcript in the Het hearts, both Het sham and Het TAC samples showed
that MYBPC3 transcript expressed from the truncated allele comprised
approximately 10% of total transcript. Also, TAC caused a ~20% increase in
MYBPC3 transcript compared to Het sham levels, with an equal increase in both
wild-type and truncated allele. This data indicates that MYBPC3 expression is not
able to increase much beyond its baseline level in Het hearts in response to
hypertrophic remodeling. The data also shows that the truncated allele is
expressed, although it is expressed as a minor component of total MYBPC3
transcript level.
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Figure 25. Heat Map of Genes Differentially Regulated in Het Sham vs. WT
Sham.
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Up-Regulated in Het Sham vs. WT Sham
Description
neuronal acetylcholine receptor subunit alpha-2
nuclear receptor subfamily 4 group A member 3
zinc finger and BTB domain-containing protein
mitogen-activated protein kinase kinase kinase
cyclic AMP-dependent transcription factor ATF-3
peptidyl-prolyl cis-trans isomerase FKBP5
apoptosis signal-regulating kinase 2
membrane-spanning 4-domains subfamily A member
cytochrome P450 2B10
thrombospondin-1
disintegrin-like metalloprotease
plexin-A2 precursor
arylsulfatase B precursor
PPAR gamma coactivator variant
peroxisome proliferator-activated receptor gamma
dow nregulated in renal cell carcinoma
predicted gene 12250
stearoyl-CoA desaturase 4
E3 ubiquitin-protein ligase RNF144B
calcipressin-1
Dow n-Regulated in Het Sham vs. WT Sham
Gene
Description
Dos
protein Dos
Erlin1
erlin-1
Id1
DNA-binding protein inhibitor ID-1
Telo2
telomere length regulation protein TEL2 homolog
Cyr61
protein CYR61 precursor
Srm
spermidine synthase
Alas2
5-aminolevulinate synthase
Klf2
Krueppel-like factor 2
Cldn5
claudin-5
Rn4.5s
4.5S RNA
Dusp1
dual specificity protein phosphatase 1
Cyp26b1 cytochrome P450, family 26, subfamily b
Ier2
immediate early response gene 2 protein
AK140896 hypothetical protein
Hba-a2
hemoglobin alpha, adult chain 2
Dkk3
dickkopf-related protein 3 precursor
Apold1
apolipoprotein L domain-containing protein 1
Egr1
early grow th response protein 1
Lrrc55
leucine-rich repeat-containing protein 55
Gm16517 tubulin polyglutamylase complex subunit 1
Tnf
tumor necrosis factor
Fos
proto-oncogene c-Fos
Myl7
myosin regulatory light chain 2, atrial
Gene
Chrna2
Nr4a3
Zbtb16
Map3k6
Atf3
Fkbp5
ASK2
Ms4a6b
Cyp2b10
Thbs1
Adamts9
Plxna2
Arsb
PGC-1v
Ppargc1a
Fam107a
Gm12250
Scd4
Rnf144b
Rcan1

Norm alized Counts per Million
WT Sham Het Sham WT TAC Het TAC
1.03
3.15
2.36
1.40
4.46
12.82
2.59
1.18
53.98
123.30
47.12
47.41
8.14
17.96
5.89
6.56
11.82
25.10
9.82
3.65
16.19
34.32
13.43
12.29
3.94
8.29
3.06
3.14
2.83
5.68
3.22
2.92
3.94
7.91
2.98
2.30
20.91
40.00
24.58
10.27
15.17
28.02
15.86
16.05
37.10
63.64
41.38
37.87
440.67
751.29
347.25
357.39
95.79
161.53
62.74
64.35
95.79
161.53
62.74
64.35
12.34
20.65
6.52
8.14
22.62
36.24
3.30
3.20
12.08
19.19
12.09
9.20
34.96
55.12
35.02
32.93
51.15
76.93
132.40
221.28
Norm alized Counts per Million
WT Sham Het Sham WT TAC Het TAC
14.39
8.44
12.80
15.54
8.57
4.99
11.31
8.25
18.51
10.59
29.37
19.75
8.05
4.53
6.67
8.19
100.25
55.74
131.45
91.79
6.77
3.61
6.28
8.53
20.82
10.82
30.94
26.48
29.47
15.05
56.38
37.53
7.11
3.45
10.99
8.42
22.62
10.82
10.99
5.78
119.96
56.12
159.10
94.59
8.40
3.92
9.50
6.62
15.59
7.22
21.28
11.67
11.57
4.99
6.36
9.76
937.46
399.67
939.10
835.18
4.03
1.69
5.58
8.86
35.73
14.59
63.61
31.36
200.84
63.87
332.17
117.65
2.66
0.84
2.59
3.03
2.83
0.77
2.28
3.70
2.31
0.61
5.10
2.08
18.94
3.07
36.44
7.74
46.44
5.99
0.86
0.73

Table 8. Genes Up and Down Regulated in Het Sham vs. WT Sham.
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Figure 26. Genes Differentially Regulated in Het TAC vs. WT TAC.
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Gene
Psca
Spon2
Arc
CRLM3
Crlf1
Dusp4
S100a9
Pdlim3
Slc12a9
Bex2
Slc38a1
Fstl4
mKIAA1061
Itgb1bp3
Amdhd2
Dusp26
Fgf6
Krt80
Nbl1
Degs2
Hspbp1
Nppa
Rcan1
Ndrg4
Ncln
Ncam1
Tspo
Baiap2l1
Zmym6
Dkk3
Ltbp2
Sema3f
Cnpy3
Arhgap27
AK080187
Lsm6
Pura
Pfkl
Loxl1
Pi16
Car3
Supt3h
Gpx1

Up-Regulated in Het TAC vs. WT TAC
Description
prostate stem cell antigen precursor
spondin-2 precursor
activity-regulated cytoskeleton-associated
cytokine receptor like molecule 3
cytokine receptor-like factor 1 precursor
dual specificity protein phosphatase 4
protein S100-A9
PDZ and LIM domain protein 3
solute carrier family 12 member 9
protein BEX2
sodium-coupled neutral amino acid transporter 1
follistatin-related protein 4 precursor
m-D/Bsp120I 1-1 mRNA
nicotinamide riboside kinase 2
PUTATIVE GLCNAC 6-P DEACETYLASE
dual specificity protein phosphatase 26
fibroblast growth factor 6 precursor
keratin, type II cytoskeletal 80
neuroblastoma suppressor of tumorigenicity 1
sphingolipid delta(4)-desaturase/C4-hydroxylase
hsp70-binding protein 1
atrial natriuretic factor
calcipressin-1
protein NDRG4
nicalin precursor
neural cell adhesion molecule 1
translocator protein
brain-specific angiogenesis inhibitor
Zmym6 protein
dickkopf-related protein 3 precursor
latent-transforming growth factor beta-binding
semaphorin-3F
Protein associated with Tlr4
rho GTPase-activating protein 27
actin, alpha 2, smooth muscle, aorta
U6 snRNA-associated Sm-like protein LSm6
transcriptional activator protein Pur-alpha
6-phosphofructokinase, liver type
lysyl oxidase homolog 1 precursor
peptidase inhibitor 16
carbonic anhydrase 3
Suppressor of Ty 3 homolog
glutathione peroxidase 1

Norm alized Counts per Million
WT Sham Het Sham WT TAC Het TAC
0.00
0.00
0.24
21.94
1.97
1.54
0.55
3.42
1.29
1.38
2.12
8.75
0.09
0.46
0.71
2.75
0.17
0.61
1.18
4.49
1.29
1.15
1.02
3.65
4.11
6.37
3.06
9.76
25.96
19.65
16.41
46.85
5.14
3.92
3.06
7.41
2.66
1.46
1.73
3.98
4.80
5.14
4.08
8.92
5.57
4.61
5.10
11.05
5.57
4.61
5.10
11.05
22.36
24.26
50.65
104.75
3.17
2.15
2.98
6.06
1.54
1.92
2.91
5.44
1.29
1.46
3.14
5.78
3.26
3.22
4.16
7.52
6.51
8.06
9.58
17.00
6.60
5.22
5.26
9.26
13.02
9.83
9.11
15.77
362.27
292.81
2631.20
4514.63
51.15
76.93
132.40
221.28
28.53
28.33
43.82
72.38
18.34
12.74
12.49
20.59
5.14
5.45
5.81
9.54
15.08
11.75
14.06
22.72
10.54
12.13
12.96
20.76
6.34
6.22
6.52
10.38
4.03
1.69
5.58
8.86
1.29
2.15
8.72
13.86
5.74
7.45
8.17
12.96
9.43
7.68
8.40
13.18
5.74
7.14
6.83
10.72
7.45
7.68
7.70
12.01
8.31
8.44
9.74
15.04
8.48
7.75
9.58
14.70
70.35
64.49
64.31
98.58
7.20
7.06
10.99
16.83
24.08
22.57
42.01
63.68
25.53
24.11
7.93
12.01
9.34
7.83
8.64
13.02
21.08
18.50
33.06
49.77

Table 9. Genes Up-Regulated in Het TAC vs. WT TAC.

128

Gene
Dusp1
Ccdc63
Kcnv2
Ier2
Rn4.5s
Ddx3y
Ddx3xchrYabca8a
Ms4a4d
Penk
G0s2
Apold1
BC157982
Lgi1
Thbs1
AK035873
Tnf
Atf3
Egr1
Fos

Dow n-Regulated in Het TAC vs. WT TAC
Description
dual specificity protein phosphatase 1
coiled-coil domain-containing protein 63
potassium voltage-gated channel subfamily V
immediate early response gene 2 protein
4.5S RNA
ATP-dependent RNA helicase DDX3Y
SubName: Full=Ddx3x protein;
ABC transporter A subfamily member
membrane-spanning 4-domains subfamily A member
proenkephalin-A
putative lymphocyte G0/G1 switch protein 2
apolipoprotein L domain-containing protein 1
similar to COMPLEMENT COMPONENT C7 PRECURSOR
leucine-rich glioma-inactivated 1 protein precursor
thrombospondin-1
leucine-rich, glioma inactivated 1
tumor necrosis factor
cyclic AMP-dependent transcription factor ATF-3
early growth response protein 1
proto-oncogene c-Fos

Norm alized Counts per Million
WT Sham Het Sham WT TAC Het TAC
119.96
56.12
159.10
94.59
2.57
3.53
14.21
8.42
14.99
12.51
7.46
4.26
15.59
7.22
21.28
11.67
22.62
10.82
10.99
5.78
0.00
0.00
47.98
25.19
0.00
0.00
47.98
25.19
26.65
18.58
19.47
9.99
13.45
12.05
12.56
6.40
11.48
9.90
37.46
18.68
63.83
39.84
48.45
23.96
35.73
14.59
63.61
31.36
1.29
1.54
14.92
7.01
13.62
16.97
20.18
9.15
20.91
40.00
24.58
10.27
8.57
9.90
13.19
5.50
2.31
0.61
5.10
2.08
11.82
25.10
9.82
3.65
200.84
63.87
332.17
117.65
18.94
3.07
36.44
7.74

Table 10. Genes Down-Regulated in Het TAC vs. WT TAC.
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Figure 27. Validation of RNA-Seq Reads with qPCR.
Levels of transcript were assessed by qPCR to confirm the findings of RNA-Seq
using primers that recognized high-copy number genes with 100+ counts/million
reads (Fhl1, Rcan1), medium copy number genes with 20 – 100 counts/million
reads (Tgfb2, Pi16), and low copy number genes with <1 – 20 counts/million
reads (Atf3, Fos, Gss). Relative gene expression in qPCR normalized against
GAPDH expression. N=4 for qPCR experiments. * P<0.05 vs. Sham, # P<0.05
vs. WT, † P<0.001 false discovery rate test sham vs. TAC, ‡ P<0.001 false
discovery rate test WT vs. Het.
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5.4 Discussion
In this study I aimed to determine if heterozygous carriers of MYBPC3
truncation mutations are predisposed to more severe hypertrophy following
cardiovascular stress induced by TAC. These experiments were also designed to
interrogate the effect of haploinsufficiency of MYBPC3 on the development of
cardiac dysfunction. Previous work using this strain of mouse has shown that the
heterozygous animal has a normal cMyBP-C compliment, despite reduced
transcript levels, with some dysfunction in force development and diastolic
function (McConnell, Jones et al. 1999, Barefield, Kumar et al. 2014). Other
heterozygous MYBPC3 truncation mutation models do show a reduction in
cMyBP-C and phenotypes showing more profound dysfunction than what has
been shown in this model (Harris, Bartley et al. 2002, Vignier, Schlossarek et al.
2009). Therefore, we aimed to determine if additional stress would unmask
haploinsufficiency of MYBPC3 resulting in reduced cMyBP-C levels and
worsened prognosis. The results of this study show various impairments in the
heterozygous genotype following stress, suggesting that these mice do exhibit a
differential response to TAC induced pressure-overload stress. Furthermore, we
have identified a transient reduction in cMyBP-C levels that may play a role in
worsening of cardiac function.
The results from this study show that WT and heterozygous mice were
subjected to an equal amount of pressure overload as assessed by transverse
aortic blood flow velocity. However, HW:BW measurements show that Het hearts
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were significantly more hypertrophied than WT 12 weeks following TAC, while
both TAC groups showed significant hypertrophy compared to sham control.
Additional evidence for the hypertrophic phenotype and verification of the TAC
procedure via qPCR showed significantly elevated transcript levels of MYH7 and
NPPA in both TAC groups compared to Sham, but did not show any changes
between WT and Het TAC hearts. These findings were supported by
measurement of protein levels of β-MHC that show a similar significant increase
in both TAC groups compared to sham. This data concludes that Het hearts
develop more robust hypertrophy following pressure-overload stress.
Despite the significantly heavier heterozygous hearts, left ventricular
septum and posterior wall thickness were not significantly altered between WT
and Het following TAC. In both TAC groups internal diameter was significantly
increased at peak systole at four weeks, suggesting contractile deficits which are
reflected in the reduced ejection fraction, whereas at 12 weeks diastolic internal
diameter was significantly increased compared to sham, suggesting the onset of
dilation. Importantly a significant decrease in contractile function was observed in
the Het mice compared to WT at both four and 12 weeks following TAC, with
reduced ejection fraction. These reductions were in addition to already
significantly reduced systolic function in both WT and Het TAC compared to their
sham controls at both time points. These findings suggest that the heterozygous
heart is more susceptible to the onset of hypertrophy and dysfunction following
cardiac stress.
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MYBPC3 transcript and cMyBP-C levels were assessed to determine if
haploinsufficiency occurred following cardiac stress. Levels of MYBPC3
transcript measured by qPCR in Het sham and TAC mice were approximately
40% lower compared to respective WT controls, but did not differ significantly
between Het sham and Het TAC groups. This alteration in transcript is similar to
the reduced transcript level in the Het mouse under naïve conditions compared
to WT (McConnell, Jones et al. 1999, Barefield, Kumar et al. 2014). These
findings suggest that there is no significant increase in MYBPC3 expression in
the Het following TAC. Also, the level of MYBPC3 transcript was not elevated in
WT TAC compared to WT sham at four or 12 weeks post-surgery, suggesting
that either the hypertrophic response was reduced at this time point, or that WT
mice do not require additional MYBPC3 expression during hypertrophy.
The analysis of cMyBP-C levels in the myofilaments of each group
by western blot showed that there is a significant reduction in cMyBP-C at the
four week time point, and this reduction occurs to the same extent in both sham
and TAC operated heterozygous mice. However, 12 weeks after surgery cMyBPC levels return to WT levels in heterozygous myofilaments, with no significant
changes between groups, similar to baseline. This suggests that cMyBP-C is
transiently reduced from a normal stoichiometry at baseline, and this reduction is
recovered sometime between four and 12 weeks. The fact that this reduction in
protein occurs in both TAC and sham heterozygous mice suggest that
hypertrophy is not responsible for this decrease. The reduced cMyBP-C content
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may be due to alterations in protein turnover in response to surgical inflammatory
stress, but this remains enigmatic. Phosphorylation of cMyBP-C also differs with
time, whereas phosphorylated species of cMyBP-C tended to be higher at four
weeks, by 12 weeks they were unchanged or reduced compared to their sham
controls. This is likely due to increased β-adrenergic signaling early in
hypertrophy, causing hyperphosphorylation of cMyBP-C and cTnI at four weeks,
and reduced PKA-target phosphorylation has been well established in the
development of HF (Tong, Gaffin et al. 2004). Unexpectedly, Het sham hearts at
four weeks showed a trend towards elevated phosphorylated cMyBP-C, which
provides a confounding factor for statistical analysis. This alteration in
phosphorylation status at Ser-273 and S-282 of cMyBP-C was not seen under
baseline conditions and may be associated with other changes seen in Het sham
at four weeks that were not seen at baseline, such as decreased cMyBP-C
content.
The results of the force-pCa experiments provide several interesting
insights into the dysfunction occurring in heterozygous cardiomyocytes. We have
shown in the baseline experiments that cardiomyocytes from heterozygous
hearts have reduced maximal force generation while retaining normal cMyBP-C
levels (Barefield, Kumar et al. 2014). Results from the current study show
expected deficits in force generation in both TAC groups. However, impaired
force generation persists in Het sham cells, consistent with the previous study.
Heterozygous hearts also show blunted length-dependent increases in force
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development at four weeks, and this alteration is absent by 12 weeks. This
suggests that despite the greater impairment of force generation 12 weeks postsurgery, the heterozygous genotype regains the ability to increase force
generation following stretch. One notable difference in the Het cells between four
and 12 weeks is their cMyBP-C content recovery. The role of cMyBP-C in lengthdependent activation is a new and active area of inquiry, and the data from this
experiment demonstrate the potential for cMyBP-C to regulate stretch sensitivity
of cardiomyocytes.
Other notable alterations occur in Ca2+ sensitivity of force development,
with both heterozygous groups showing a significant Ca2+ sensitization at short
sarcomere lengths at four weeks as well as a blunted length-dependent increase
in sensitivity at four weeks. This deficit in length dependent Ca2+ sensitization
was mildly attenuated by 12 weeks. These observations are again different from
the data obtained at baseline, where Het cardiomyocytes did not show any
significant difference in Ca2+ sensitivity or length-dependent activation.
Understanding why this change occurs is difficult, as at four weeks cMyBP-C
phosphorylation is altered with normal cTnI phosphorylation in the Het sham
cardiomyocytes. However, at 12 weeks Het cardiomyocytes show normal
cMyBP-C levels and phosphorylation, but do show an increase in cTnI
phosphorylation which would suggest a Ca2+ desensitization.
The RNA-Seq experiment was performed to assess changes in the
ubiquitin

proteasome system

and nonsense-mediated RNA degradation
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pathways, as well as to identify novel changes in gene expression the Het hearts
in order to identify alterations that occur as a result of haploinsufficiency of
MYBPC3.

The

hypothesis

that

alterations

in

nonsense-mediated

RNA

degradation or the ubiquitin-proteasome system cause dysfunction in the Het
was not supported by this data, as no changes in proteasome associated genes
or in pathways associated with RNA degradation were identified. Interestingly,
one of the common Het up-regulated genes in both sham and TAC compared to
WT controls was calcipressin, the anti-hypertrophic regulator of calcineurin. Also
interesting were the alterations observed in Het sham compared to WT sham.
Specifically, altered regulation was observed in several extracellular matrix
remodeling genes including the up-regulation of thrombospondin and matrix
metaloproteases. These observations indicate a role for remodeling prior to the
onset of hypertrophy, which may suggest a future direction looking at the role of
fibroblasts and infiltrating immune cells in the early stages of pathology in Het
hearts.
The results of this study clearly demonstrate that following pressureoverload stress heterozygous MYBPC3 truncation mutation carriers develop
more severe hypertrophy with worsened cardiac function compared to wild type.
These deficits can be explained by a transient reduction in cMyBP-C levels in the
heart due to haploinsufficiency in the heterozygote. However, due to the
evidence that under naïve conditions these mice have subtle defects in
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cardiomyocyte contractility, it is likely that another mechanism is partly
responsible for these impairments.
The

data

from

these

experiments

confirm

our

hypothesis

that

heterozygous mice are at a greater risk for cardiomyopathy following stress, and
this is likely due to the initial dysfunction under naïve conditions which is
exacerbated following stress. It remains unclear if reduced cMyBP-C protein level
precedes the development of hypertrophy or follows it. We have shown here that
heterozygous mice have a reduction in cMyBP-C levels under both Sham and
TAC conditions four weeks post-surgery. This is an interesting observation and
may suggest that stress from sham surgery alone, which is a considerably
invasive surgical procedure, is able to exert a stress that causes reduced
cMyBP-C expression. Whether this is mediated through inflammatory pathways
or disruptions in protein turnover mechanisms remains unclear.
In the human population heterozygous HCM carriers typically develop
symptomatic HCM later in life suggesting a change that triggers the onset of
disease. Although samples from symptomatic HCM carriers have shown a
reduction in total cMyBP-C levels, it is unknown if asymptomatic HCM mutation
carriers have a deficit of cMyBP-C. Understanding whether reduced cMyBP-C is
a cause or result of the onset of HCM in heterozygous truncation mutant carriers
has implications on the mechanism of pathogenesis and targets for therapy.

CHAPTER SIX
TURNOVER OF cMyBP-C

6.1 Introduction
Under naïve conditions heterozygous MYBPC3 mice show normal levels
of cMyBP-C yet also exhibit functional impairments at the single cell and wholeorgan level (Barefield, Kumar et al. 2014). The only reported molecular deficit in
these Het hearts is that MYBPC3 gene expression level is significantly lower than
WT. The mechanism by which reduced gene dosage may lead to the onset of
this observed dysfunction may provide a novel and early therapeutic target for
carriers of this type of mutation. Therefore, it is important to determine what
mechanisms are responsible for this dysfunction as they may be responsible for
the early development of functional impairments and the onset of HCM.
To assess the mechanism of Het dysfunction two approaches were
attempted. The first was to look at the effect of small reductions in cMyBP-C
level, as had been shown in human MYBPC3 carrier hearts. Assessing this
function requires knocking down cMyBP-C in a functioning adult cardiomyocyte,
in order to measure functional impairments caused by reduced cMyBP-C.
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However, turnover of cMyBP-C proved to be too slow in adult rat cardiomyocytes
to use this system.
The second avenue of inquiry builds on the efforts to knock down
MYBPC3. Sarcomere proteins assemble with well-defined stoichiometry and
have a defined turnover rate. Large proteins that are integral to sarcomere
structure have very long half-life (15 days for myosin heavy chain), with smaller
proteins typically having shorter half-life in the sarcomere (3-5 days for the
troponins) (Boateng and Goldspink 2008). As demonstrated in the attempted
knock-down experiments, cMyBP-C has a long half-life. However, examining
protein turnover in the context of altered MYBPC3 expression, as seen in the Het
mice, may provide a mechanism for the dysfunction observed under naïve
conditions and post-TAC.
As exogenous cMyBP-C has been shown to exchange passively with
endogenous cMyBP-C in in vitro exchange assays, I hypothesized that synthesis
of additional cMyBP-C will increase turnover of sarcomeric cMyBP-C. Turnover is
assessed using

35S

labeled amino acid media to label all proteins synthesized in

a certain time frame followed by viral overexpression or knock-down of MYBPC3
to modulate gene dosage and protein turnover. Data supporting this hypothesis
was expected to show that knocking down MYBPC3 transcript causes new
cMyBP-C synthesis to reduce, resulting in less new protein exchanging with
endogenous labeled protein. Also, MYBPC3 overexpression was hypothesized to
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increase the amount of cMyBP-C synthesized, causing additional exchange and
a reduction in the amount of labeled protein present in the sarcomere.

6.2 Results
6.2.1 Knock-Down of MYBPC3
In order to study the effect of altered cMyBP-C stoichiometry in the
sarcomere, MYBPC3 was knocked down in adult rat ventricular cardiomyocytes
and neonatal rat cardiomyocytes. To accomplish this, lipid transfection of siRNA
or adenoviral delivery of siRNA was used to knock down cMyBP-C. The initial
experimental design called for performing functional measurements of unloaded
shortening using an IonOptix system following cMyBP-C knock-down.
Rat ventricular cardiomyocytes were isolated as described in the methods
section and were treated with adenovirus expressing siRNA or an adenovirus
with an empty vector, and were cultured for up to 48 hours. Protein and mRNA
were isolated as described. Levels of MYBPC3 were significantly reduced in
adenovirus-treated cardiomyocytes compared to vector-treated, normalized to
GAPDH expression; however, protein levels were not significantly altered at this
time point (Figure 28). As the function and viability of adult cardiomyocytes are
already in decline at 48 hours, it was not deemed prudent to continue these
experiments in this system. The resistance of cMyBP-C to knockdown is not
surprising due to the long half-life of sarcomere proteins.
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In order to assess how long it would take to knock-down cMyBP-C,
neonatal rat cardiomyocytes were cultured with siRNA for seven days to knock
down MYBPC3 expression. In this model, cMyBP-C levels normalized to actin
were significantly reduced in the siRNA adenovirus treated cells compared to
empty vector at seven days post-infection (Figure 28). These findings reinforce
the notion that cMyBP-C would be difficult to knock down within 48 hours in order
to study functional effects of reduced protein level in adult cardiomyocytes.
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Figure 28. Knock-Down of MYBPC3.
A, Transcript level of MYBPC3 normalized to GAPDH expression assessed by
qPCR shows that at two days post infection adult rat cardiomyocyte MYBPC3
expression was virtually abolished. B, Despite this efficient transcript knock-down
levels of cMyBP-C normalized to α-tropomyosin were unchanged in adult rat
cardiomyocytes 48 hours post-infection. C, However, cMyBP-C levels normalized
to α-tropomyosin were significantly reduced 7 days post-infection in neonatal rat
cardiomyocytes. UI: uninfected; EV: empty vector; GPF: green fluorescent
protein expressing; siRNA: MYBPC3 siRNA. (N=4) *P<0.05, t-test.
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6.2.2 Determination of Gene Expression on Protein Turnover
In order to determine if gene dosage plays a role in turnover of cMyBP-C
adenoviral knock-down and overexpression of MYBPC was performed to reduce
and increase the gene dosage, respectively (described fully in the methods
section). These studies were originally performed in neonatal rat cardiomyocytes
with a one day pulse of

35S

labeled Met/Cys amino acids, as it was assumed

long-culture periods would be required for proper turnover. Labeling of
myofilament proteins with 12 hours of

35S

media was successful and this labeling

persisted for the length of the culture period (four days). Initial experiments
demonstrated that the MYBPC3 overexpressing cells showed an increase in a
larger labeled band of cMyBP-C (not shown), which indicates that new synthesis
of labeled protein was occurring following removal of the labeled media,
potentially resulting from liberation of labeled Met/Cys amino acids from natural
protein degradation and recycling mechanisms. Therefore, following the initial
pulse of labeled media, a wash-out period was added prior to treating with virus.
Isolation of myofilaments from these cells showed good incorporation of the
label; however, due to the small amount of myofilaments present in neonatal
cardiomyocytes, levels of cMyBP-C were difficult to measure in any group
(Figure 24). Due to this complication, this pulse-chase protocol has been
adapted for rat ventricular cardiomyocytes which were shown to be labeled with
short (1-4 hour) pulses (data not shown). Virally-mediated turnover experiments
are currently ongoing.

143

Figure 29. Phosphor-Storage Screen Image of 35S Labeled
Cardiomyocytes.
Adult rat cardiomyocytes were treated either with empty adenovirus (empty),
adenovirus containing shRNA for MYBPC3 (shMYBPC3), or carrying MYBPC3.
Myofilament proteins from neonatal cells show low levels of myosin and actin
compared to adult, with cMyBP-C too low to accurately quantify.
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6.2.3 MYBPC3 Gene Dosage Directly Alters Force Development
Despite the technical difficulties in calculating protein turnover by pulsechase, the hypothesis that MYBPC3 gene expression has a direct link on
cardiomyocyte contractility can be tested using a transgenic mouse model. A
mouse model carrying transgenically expressed MYBPC3 crossed into the (t/t)
background with no endogenous protein was previously generated and available
for these experiments, named the WT(t/t) mouse. This mouse has two truncated
alleles that as previously shown do not produce any protein. The transgene
encodes MYBPC3 and expresses normal cMyBP-C which rescues the dilated
phenotype observed in the t/t mouse. Also, the MYBPC3 is expressed
approximately 5-fold higher than non-transgenic WT mice (Sadayappan Lab,
Data in submission). Although cMyBP-C is overexpressed, these mice are
normal, with cMyBP-C stoichiometry equal to non-transgenic WT. Using this
model it is possible to test whether the truncated allele alone is sufficient for the
reduction in force observed in the Het mice under normal conditions, as the
WT(t/t) mouse has two of these alleles. Also, the WT(t/t) and the Het mice both
have normal cMyBP-C levels. If reduced gene dosage is able to directly cause
the reduction in force observed in the Het cardiomyocytes, then the WT(t/t)
should show no significant reduction. However, if the truncated allele acts as a
poison polypeptide, then the WT(t/t) should show significant dysfunction
compared to non-transgenic WT controls.

145
To test this hypothesis force-pCa measurements were performed on
WT(t/t) cardiomyocytes which were compared to non-transgenic WT and Het
values. The results of this experiment demonstrated that transgenic WT
cardiomyocytes show normal maximal force development despite carrying two
truncated alleles, with Het cardiomyocytes showing significantly reduced force
generation compared to both transgenic and non-transgenic WT groups.
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Figure 30. Gene Dosage and Cardiomyocyte Force Generation.
WT(NTG) and WT(TG) cardiomyocytes showed equal maximal force generation
at both sarcomere lengths. Het cardiomyocytes generated a significantly lower
amount of force compared to both NTG and TG WT groups. N=3 hearts, 3
cells/heart, * P<0.05 vs. WT(NTG); # P<0.05 vs. WT(TG).
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6.3 Discussion
The experiments described in this section aimed to explain how cMyBP-C
content in the sarcomere contributes to the development of force in single
cardiomyocytes. It became clear that knocking down cMyBP-C in cultured rat
cardiomyocytes was not a viable approach as the time required to reduce the
level of cMyBP-C was too long to perform the experiments originally proposed.
However, the long-lived nature of cMyBP-C in the sarcomere is an interesting
property that could be regulated by expression levels of MYBPC3, and therefore
may be a mechanism by which to explain the dysfunction observed under
baseline conditions.
Attempting to probe this mechanism with a pulse-chase assay was unable
to be completed. However, assessing the relationship between transcript level
and cardiomyocyte function was possible using a transgenic mouse model
overexpressing WT MYBPC3 in the t/t background. The results of that
experiment show that the presence of the t/t alleles do not cause contractile
dysfunction as observed in the Het cardiomyocytes. This observation provides
additional evidence against the poison polypeptide hypothesis that has remained
persistent in the literature despite lack of evidence for truncated protein
expression. Also, with WT transgenic, non-transgenic, and Het sarcomeres all
containing the same amount of cMyBP-C, the results from this experiment
reinforce the results from baseline analysis showing that there is something
fundamentally wrong with Het cardiomyocytes, independent of cMyBP-C content.

CHAPTER SEVEN
FUTURE DIRECTIONS AND CONCLUSIONS

The data reported in this work support the initial hypothesis that carriers of
MYBPC3 truncation mutations are predisposed to the development of
cardiomyopathy due to subtle deficits under normal conditions and exacerbated
pathology following stress. While these findings add insight into the current state
of this area of research, several additional questions have arisen from this line of
inquiry regarding the mechanisms underlying these observed functional deficits.

7.1 Altered Function with Normal Protein Level
As previously discussed, the observation that naïve Het mice exhibited
contractile

abnormalities

was

surprising,

given

the

normal

cMyBP-C

stoichiometry observed in those hearts. In order to explain this observation,
additional work is required to assess whether 1) the truncated allele produces a
potentially pathogenic fragment that has yet to be identified; or 2) decreased
transcript levels of MYBPC3 in the Het cardiomyocyte causes a deficit that is not
related to absolute protein stoichiometry, such as altered turnover and/or posttranslational modifications. While the work proposed and completed in this
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project focused on evaluating the outcome of these mice following stress, the
questions that have been raised from these results provide some interesting
avenues for future research.

7.2 Haploinsufficiency vs. Poison Polypeptide
The mechanisms by which these heterozygous truncation mutations
cause dysfunction have been hotly debated and have focused primarily on either
haploinsufficiency or a poison polypeptide model. The results of this study, taken
together with other recent findings, suggest that the poison polypeptide is unlikely
to be responsible. Fragments of mutant cMyBP-C have rarely been identified in
human patients or mouse models of MYBPC3 truncation mutant carriers, but
despite this lack of evidence the possibility of a small amount of mutant protein
exerting a pathological effect remains. The lack of identified protein fragments is
certainly strong evidence against this model, but until recently it has been unclear
how much fragmented cMyBP-C protein would be required to cause contractile
deficits.
In a recent paper, Witayavanitkul et al. administered recombinant N’terminal fragments of cMyBP-C to permeabilized human myocardial tissue
(Witayavanitkul, Ait Mou et al. 2014). The rationale for this study was to
determine the pathological potential of the cleavage and release of the N’terminal residues of cMyBP-C following calpain cleavage that have been
observed by the Sadayappan lab. In the Witayavanitkul et al. study, reduction in
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force was observed with an EC50 of 4.41μM of cMyBP-C C0-C1f (the first two N’terminal domains of cMyBP-C, with a short fragment of the M domain) and a
maximal reduction in force at ~30μM. The concentration of cMyBP-C in the
sarcomere is estimated to be ~15μM (Witayavanitkul, Ait Mou et al. 2014). Using
this information to understand the heterozygous poison polypeptide model, it
becomes clear that the amount of cMyBP-C fragment required to impair
contractility is too high to have remained undetected in patient biopsies and
mouse models. As this truncated protein or similar proteins have not been
detected by Western blot, these observations are unlikely to be explainable by a
poison polypeptide mechanism. However, these observations alone are not
sufficient to distinguish between haploinsufficiency, alterations in signaling
pathways, or dysfunction in RNA and protein degradation pathways.
Another potential explanation for dysfunction has been proposed over the
years and has been recently studied by the Carrier lab (Schlossarek,
Schuermann et al. 2012). This model suggests that misfolded proteins or mutant
transcripts may overwhelm degradation pathways, causing dysfunction. The
RNA-Seq experiments reported in this work were initially planned in order to
study any underlying alterations in these pathways. However, analysis of this
data did not show any alterations in Het hearts compared to WT in either the
ubiquitin proteasome pathway or in genes encoding for RNA degradation
pathways. However, improper protein degradation may still play a role in the
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pathogenesis in these mutant carriers and certainly warrants additional
investigation.
In the current work, decreased levels of cMyBP-C were shown at four
weeks, with return to normal levels by 12 weeks. Clearly the temporal resolution
of the experimental design used in this study is not sufficient to capture the timecourse of reduction and restoration of cMyBP-C levels. Therefore, it can still be
asked whether reduced cMyBP-C levels initiate hypertrophy, or if hypertrophy
causes reduced cMyBP-C levels. Recently the Moss lab used an inducible
knock-out MYBPC3 mouse model to show that reduced cMyBP-C initiates DCM
(Chen, Patel et al. 2012). In this model, cMyBP-C levels are reduced to
approximately 50% of untreated after 2 weeks, with an almost complete knockout 8 weeks following tamoxifen induction. Despite the efficient knock-down,
systolic function remained unaltered 20 weeks post-treatment although
hypertrophy and diastolic dysfunction were evident (Chen, Patel et al. 2012). This
supports the idea that reduced cMyBP-C can be causative for the development
of hypertrophy. It remains to be seen whether this reduction of cMyBP-C is
causative for HCM in human heterozygous MYBPC3 carriers.

7.3 Decreased Transcript as a Mechanism of Dysfunction
Following the observation that Het naïve mice showed dysfunction despite
normal cMyBP-C levels, several experiments were performed to assess whether
gene dosage could directly explain this phenomenon. I hypothesized that
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reduced MYBPC3 gene expression causes reduced cMyBP-C production, which
leads to slower protein turnover in the sarcomere. Following the observations
that MYBPC3 transcript was decreased, with preserved cMyBP-C levels and a
reduction in force generation in Het naïve cardiomyocytes, the role of gene dose
on protein turnover was assessed. To assess this, a pulse-chase experiment was
performed using

35S

labeled amino acids in neonatal and adult rat

cardiomyocytes. A consequence of reduced protein turnover which would
increase protein half-life and could allow cMyBP-C to become more heavily
modified by functionally deleterious PTMs, particularly irreversible oxidative
modifications.
If gene dose regulation of protein turnover proves to be a viable
mechanism for contractile dysfunction, it still remains to be seen how these
changes cause alterations in cardiomyocyte function. One possibility and future
direction is to examine whether expression levels of MYBPC3 influences the rate
of protein turnover in the sarcomere, with the hypothesis that reduced expression
would lead to a longer cMyBP-C half-life. This hypothesis is supported from the
cardiomyocyte force generation data outlined in chapter six, where decreases in
force generation in Het mice were reversed with overexpression of MYBPC3
despite the presence of truncated alleles in the genetic background. Recent
evidence from the Solaro lab has shown that cMyBP-C and other sarcomere
proteins can be post-translationally regulated with oxidative modifications such
as glutathionylation (Patel, Wilder et al. 2013). As cMyBP-C has been well
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established as a regulatory protein, these oxidative modifications may cause
dysfunction. If cMyBP-C did have a longer half-life in the sarcomere in
heterozygous MYBPC3 truncation carriers, these oxidative modifications may
become more deleterious as new cMyBP-C is not produced in sufficient
amounts. These oxidative modifications could interfere with native cMyBP-C
incorporation in the sarcomere, its ability to be targeted by kinases, and the
ability of cMyBP-C to interact with its N’-terminal regulatory targets. This
mechanism by which reduced transcript leads to dysfunction would be supportive
of the notion that haploinsufficiency is occurring and would provide an
explanation for dysfunction with preserved cMyBP-C levels.

7.4 Mutations as Modifiers of Cardiovascular Disease
As HCM associated mutations are relatively common in the human
population (1:500) there is a possibility that carriers of HCM associated mutations
have hypertrophic comorbidities. Indeed, in a recent large-scale human genome
screening, the incidence of HCM associated mutations was much higher in the
human population than the predicted 1:500 frequency (Golbus, Puckelwartz et al.
2012). This is interesting in terms of diagnosis of HCM, and the detection of
pathogenic mutations in patients with diabetes, hypertension, ischemic injury, or
other cardiac pathologies.
As most of these morbidities are also relatively common in the human
population (Go, Mozaffarian et al. 2013), there is a possibility that HCM mutation
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carriers that develop cardiomyopathy also share one or more of these
comorbidities. In this case, diagnosis of HCM may not be attributed to the
mutation, as a more obvious cause of cardiomyopathy is evident. Therefore,
genetic screening for HCM causing mutations in patients with an identifiable
cause for hypertrophy may be clinically useful, especially if these comorbidities
are predictive of more severe cases of HCM and require more aggressive
treatment. An investigation of the genetic background of cardiomyopathy patients
suffering from non-genetic causes may be beneficial to establish if there is an
association between undetected mutations and disease severity.

7.5 Conclusion
The results of this study demonstrate that the pathophysiological response
to cardiovascular stress is altered in heterozygous MYBPC3 truncation mutant
carriers. Due to the high prevalence of similar mutations in the human population,
understanding the mechanism by which these mutations cause pathology is
imperative. In addition, characterization of the effects of common cardiovascular
disease risk factors in this genetic background may provide an understanding of
why this disease shows such variable penetrance in families carrying similar
mutations, and what steps might be taken to minimize risk of developing
cardiomyopathy in the human population.

CHAPTER EIGHT
METHODS AND MATERIALS

8.1 Mouse model of MYBPC3 haploinsufficiency
For this study non-transgenic WT mice were used as well as a knock-in
model generated in the Siedman lab (McConnell, Jones et al. 1999) carrying a
truncation mutation in the MYBPC3 gene with either homozygous (t/t) or
heterozygous (+/t) genotypes. All mice were in the FVB/N background and all
experiments used mice between 10-12 weeks of age, including the TAC
experiments which used this age as the time period in which the surgery was
conducted. All the experiments using animals detailed in this work were
approved by the Institutional Animal Care and Use Committees at Loyola
University Chicago and followed the policies of the Guide for the Use and Care of
Laboratory Animals published by the National Institutes of Health.

8.2 In vivo TAC in Mice
This study used a transverse aortic constriction (TAC) model of pressureoverload hypertrophy. The surgical procedure was very generously taught to me
by Jop Van Berlo, MD, PhD, from the lab of Jeff Molkentin, PhD at Cincinnati
Children’s Hospital in Cincinnati, OH. Development of this technique required
155
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considerable practice, and I was given an excellent chance to practice this
surgery and validate my results while collaborating on a project for Rajesh
Kishore, PhD at Northwestern University (Verma, Krishnamurthy et al. 2012).
Preparation
Mice were anesthetized in an induction chamber with 5% vaporized
isoflurane with 100% oxygen. Animals were weighed and transferred to a nose
cone in the preparation area where their fur from neck to the level of the 6-7th rib
was shaved with an electric razor to expose the surgical site. The animal was
then transferred to a nose cone on a heated surgical table (Harvard Apparatus
50-1239) in a supine position with the forelimbs restrained using 3M Durapore™
tape. The site of incision was cleaned three times using Betadine in ethanol and
gauze pads.
Intubation
A cut down the midline was made between the level of the clavicle and the
chin with a pair of scissors (Harvard Apparatus PY2 72-8442). The skin was
gently retracted laterally, exposing the salivary glands. Using two forceps
(Harvard Apparatus PY2 72-8599) the salivary gland was gently blunt dissected
down its midline, separating into a left and right lobe. The muscle layer covering
the trachea was visible, and using the same forceps was blunt dissected down
the midline exposing the trachea. The animal was repositioned for intubation and
using a pair of curved forceps the trachea was isolated, without applying any
force to the trachea, and an intubation tube (BD 20Ga Shielded IV Catheter
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381534) with blunted needle guide was introduced into the trachea. Visualization
of the trachea ensured proper intubation is successful, as accidental intubation of
the esophagus is immediately detectable using this method. The intubation tube
was then attached to a ventilator (Hugo Sachs 845) and the mouse was
ventilated at a rate and volume that establishes proper chest inflation without the
animal gasping. Ventilator settings were determined animal-to-animal, but a
guide following a body weight range of 20g – 40g, with a tidal volume of 120µl –
240µl and respiratory rate of 148 – 124 breaths per minute was used to avoid
over-ventilation.
Thoracotomy
With the animal positioned on the ventilator in a supine position with the
animal’s head oriented toward the surgeon, the limbs were taped down, with care
taken that the intubation tube remained inserted at a proper depth. The midline
cut through the skin was continued to the level of the 4-5th rib using scissors. The
skin was spread away from the midline, exposing the ribs and chest wall. It was
important that at this stage ribs 1-3 were visible along the sternum. A pair of blunt
forceps was used to firmly grasp the left clavicle, lifting up slightly. A pair of
angled spring scissors with a blunted lower blade (Fine Science Tools 15033-09)
was inserted under the ribs, at the midline. A short cut was made with these
scissors, deviating slightly to the left, cutting through the left clavicle and the 1 st
rib on the left side of the sternum. This cut was then extended parallel to and
very close to the sternum. Staying along this course, the cut was continued up to
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the third rib, but not through the third rib. It was imperative that this cut remained
as close to the sternum as possible, and the third rib is not cut, as both of these
errors typically resulted in massive blood loss. As this step was the most painful,
the isoflurane was reduced from the initial 5% level to 2% following this step. The
midline dissection of the muscle layer covering the trachea was continued, which
opened the cavity containing the thymus under the first two ribs. Blunt retractors
(custom made bent dental wire) were used to pull the ribs laterally. This exposed
the trachea, the right and left carotid arteries, the thymus, and the jugular veins.
Transverse Aortic Constriction
The left and right lobes of the thymus were blunt dissected with forceps
and spread apart to expose the aortic arch and the base of the heart. Depending
on the strain of mouse, extensive cleaning of the aorta was required, as the
thymus was occasionally strongly attached to the aorta. Failure to clean the aorta
properly can change the diameter of the constriction and introduce variability. A
pair of hooked fine point forceps (Harvard Apparatus PY2 72-8611) was
introduced under that aorta, and then the tips were angled upwards so that the
aorta was cradled in the curve of the forceps. A 4-6cm long piece of 7-0 silk
(Teleflex 103-S), which was soaked in sterile saline prior to the procedure, was
grasped by the hooked forceps, which are then carefully pulled back under the
aorta. This resulted in the piece of silk positioned beneath the aortic arch
between the left and right carotid arteries. A blunted 27 gauge needle (Harvard
Apparatus PY2 72-2304) was positioned parallel to the transverse aorta and then
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a knot was tied tightly around this needle and the aorta. If done properly the
needle pulsated in pace with the heart. While grasping one of the free silk
threads with a pair of forceps for counterweight, the needle was removed.
Visually evaluating whether the pulsing of blood through the right carotid artery
was more severe than the left carotid artery was used as a qualitative indication
of the success of the TAC.
Closing and Recovery
The lobes of the thymus were put back together and pushed under the
ribs, and the retracted muscle layer was moved back to the midline. A 4-0 silk
suture connected to a curved taper point needle (Ethicon K871H) was used to
pierce the right side of the chest wall, just inside the joining of the sternum with
the right clavicle. The needle was then brought through the left chest wall,
avoiding the jugular vein lateral to the incision site. The suture was drawn
through and tied tightly to close the ribs. Additionally, a 6-0 silk suture (Cat
K802H) was used to make one or two interrupted sutures on the muscle layer
between the clavicle and the third rib. These sutures ensured that the chest was
sealed. Under normal conditions, the lungs did not need any additional steps to
re-inflate, as the ventilator maintained them in an inflated state throughout the
procedure. The 6-0 suture was then used to close the skin using a continuous
suture pattern. The incision site was washed again with Betadine in ethanol, and
the animal was turned over to lay prone. Buprenorphine (Reckitt Benckiser
Pharmaceuticals) at a dose of 0.5mg/kg and ampicillin (AuroMedics) at a dose of
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50 mg/kg were administered subcutaneously behind the head. The isoflurane
was turned off and the animal was allowed to regain ambulation before it was
removed from the ventilator and extubated. Animals were kept in a cage half on a
warming pad in an incubator with 100% oxygen treatment for 1-2 hours following
surgery.
Echocardiographic Verification of TAC Procedure
Proper placement and execution of the TAC procedure was evaluated
using echocardiography as soon as the animal was well enough to withstand
another procedure (typically 1 week post-op was sufficient in wild-type mice).
Blood flow velocity across the transverse aorta was measured using a Visual
Sonics Vevo 2100 echocardiography system with a 13-24 MHz transducer (MS250) normally used for large rodent echocardiography. By positioning the probe
parallel to the long axis of the heart on the animal’s right side, a full view of the
aortic arch and three major vessels was easily obtained. Using the powerDoppler imaging modality, blood flow velocities were measured. A normal mouse
under baseline conditions or following sham surgery had a transverse aortic
blood flow velocity between 600-900 mm/s, which correlated to a pressure
gradient of 3 mmHg across the transverse aorta. In an animal with a successful
TAC in place, this velocity was required to be >3000 mm/s, corresponding to a
pressure gradient of 36 mmHg. These measurements were repeated
longitudinally, and were performed at the terminal time point to ensure that the
suture had remained tied throughout the experimental period.
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8.3 Echocardiography
Echocardiography was performed using a VisualSonics Vevo 2100
imaging system (VisualSonics, FujiFilm, Toronto, Canada) with an MS550S 2156 MHz or MS250 13-24 MHz imaging transducer. Under isoflurane anesthesia
(5% for knock-down and 1.5% for sedation), the hearts were monitored for
changes in structure and morphology. Animals were measured one day prior to
surgery, and then monthly for four to 12 weeks following surgery. WT and Het
mouse hearts were subjected to analyses using noninvasive M-mode
echocardiography, pulse-wave Doppler imaging for measuring blood flow, and
tissue Doppler imaging to measure mitral valve performance.
Chamber dimension and wall thickness during systole and diastole were
measured using M-mode images. From these values, % fractional shortening
(FS) (measured as LVID;d – LVID;s / LVID;d x 100) and % ejection fraction (EF)
were determined. Power Doppler and Tissue Doppler analysis was used to
measure diastolic function via the E/A and E’/A’ ratio. Using the MS250 probe
transverse aortic velocity was measured, as previously discussed which
determined the efficacy of the TAC procedure and was used as an inclusion
criterion. Parasternal long axis images were used to measure strain, which was
assessed using the Vevo2100 image processing.

8.4 Steady-state force measurements
All force-pCa experiments were performed by Mohit Kumar, MS in the de
Tombe lab at Loyola University Chicago. Cells were prepared and analyzed for
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force-pCa relationship as previously described (van der Velden, Papp et al. 2003,
Barefield, Kumar et al. 2014). Frozen left ventricular tissue was homogenized
and filtered through a 70μm cell strainer, followed by centrifugation at 120g for 1
minute at 4°C. The cells were skinned by re-suspending the pellet in relaxing
solution (97.92 mM KOH, 6.24 mM ATP, 10 mM EGTA, 10 mM Na2CrP, 47.58
mM Kprop, 100 mM BES and 6.54 mM MgCl2) with 1% Triton-X100 and then
incubating for 10-15 minutes at room temperature on a rocking table. The Triton
was washed out by two centrifugation steps at 120g for 1 minute at 4°C with
resuspension in relaxing solution. The skinned myocytes were transferred to a
culture dish coated with 0.1% BSA. Using an inverted microscope (Leica DM
IRB) under bright field at 40x magnification, skinned myocytes were attached to
two metal micro-needles using UV-sensitive glue (Norland, Cranbury, NJ). The
micro-needles were attached to a high-speed piezo translator (ThorLabs,
Newton, NJ) and a force transducer. Myocytes were selected based on
uniformity of the cell and clear striation patterns. Myocytes were perfused via a
closely placed perfusion pipette with relaxing solution. Subsequent perfusion
used a mixture of relaxing and activating solutions with varying calcium
concentrations (pCa 10.0 – pCa 4.5) to measure force development at
sarcomere lengths of 1.9 µm and 2.3 µm. Maximal activating calcium solution
was administered at the start of the experiment to ensure proper cell attachment.
Sarcomere length (SL) was measured using FFT analysis of video images using
custom-made LabView software (National Instruments, Austin, TX). Force-pCa
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curves were fit using a modified Hill equation (P/P O = [Ca2+]n/(kn+[Ca2+]n), where
n is the Hill-slope and k is the pCa50. Cell cross-sectional elliptical area was
calculated by buckling the cell, followed by measurement using a calibrated
screen monitor. Developed force was measured at both SLs at each activating
cycle, with the baseline value of developed force subtracted from subsequent
measures. Data were not considered valid if total rundown was greater than 20%
after final maximal activation at the end of each activating cycle at both SLs. All
data were acquired by custom-made LabView software and analyzed using
Origin Pro 8.0.

8.5 Histopathology and Immunohistochemistry
To define any gross hypertrophy that resulted from deleterious effects of
MYBPC3(+/t) haploinsufficiency during myocardial stress, HW/BW ratio was
determined after TAC and isoproterenol treatment as described previously.
Gross morphology and the presence of fibrosis was assessed using Hematoxylin
& Eosin staining and Masson’s Trichrome staining of 5µm thick heart slices.
Hearts were perfused with cold cardioplegic buffer via retrograde perfusion from
insertion of a needle into the abdominal aorta. Hearts were then perfused with a
10% formalin solution via the same needle. Hearts were processed into sections
by Loyola’s histological core sample processing facility.

Localization and

integration of cMyBP-C into the sarcomere was evaluated using immunostaining
and confocal microscopy (Leica TCS SP5) using the departmental core facility.
Cryosections were used for immunofluorescence analysis with custom anti-
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cMyBP-C2-14 antibodies (N’-specific) and commercial anti-α-actinin antibodies.

8.6 Quantification of Protein Levels
Protein analysis was performed using homogenized whole-heart tissue, or
with myofilament enriched fractions. Homogenization was performed using a
mechanical bead beater, with urea buffer (50 mM Trish-HCL, pH 7.5, 4 M urea, 1
M thiourea, 0.4% CHAPS, 20 mM spermine, 20 mM DTT) for whole heart
homogenate or F-60 buffer (60 mM KCl, 30 mM Imidazole, 2 mM MgCl2) with
protease (Roche) and phosphatase (Sigma, cocktail I and II) inhibitors for
myofilament isolations. Most protein assays were resolved on 4-15% SDS-PAGE
gel cassettes from Bio-Rad (Cat# 456-1083). SDS-PAGE gels were assessed
using Coomassie Brilliant Blue or SYPRO Ruby staining for total protein, or ProQ Diamond staining for phosphorylation. Western blot was performed using a
Bio-Rad transfer system. All western blots were evaluated using the ECL+
reagent and imaged using the Typhoon Trio scanner (GE Health Systems).
Western blot protein levels were quantified using band density measurements
using ImageJ, with the target protein normalized to α-tropomyosin or actin.
Levels of cMyBP-C were measured using a multitude of site-specific
antibodies, as well as a series of phospho-site specific antibodies to assess
phosphorylation of cMyBP-C. Myofilament proteins derived from MYBPC3(+/t) and
WT hearts in the TAC and sham groups were used to measure phosphorylation
levels of Ser-273, Ser-282, and Ser-302 by Western blot using site-specific
phospho-antibodies. SDS-PAGE with large format 6.25% acrylamide gels with

165
protein samples homogenized in RIPA buffer (500mM NaCl, 50mM Tris, pH 7.5,
0.1% SDS, 0.5% NaDeocycholate, 1% Triton X-100) with protease inhibitor
(Roche) and phosphatase inhibitors (Sigma, cocktail I and II) will be used to
assess the shift in the myosin heavy chain isoforms that often accompanies
hypertrophic remodeling.

8.7 Isolation of mRNA and qPCR Analysis
Minced heart tissue was homogenized in 1mL of TriZol (BioRad) using a
bead homogenizer, and mRNA was isolated using the Aurum Total RNA Fatty
and Fibrous Tissue Kit (Cat. 732-6820, BioRad). Synthesis of cDNA from the
mRNA samples was performed using the iScript cDNA synthesis kit (Cat. 1708891, BioRad) with 1μg of mRNA template used in each reaction. Templates for
qPCR analysis were also generated using no reverse transcriptase, which were
used as negative controls. Gene expression levels were analyzed using TaqMan
primers recognizing MYBPC3 with FAM dye(Cat. Mm.PT.53a.2930640, IDT),
MYH7-FAM,

NPPA-FAM,

Mm01319006g1;

GAPDH-VIC

Mm01255748g1;

Dye,

and

Mm00486742m1;

CASQ2-VIC
4352339E,

(Cat.
Applied

Biosystems) with iTaq Probes Master Mix (Cat. 172-5131, BioRad) and analyzed
using a BioRad CFX96 thermocycler. The cycle protocol was 94°C for 10
minutes, followed by 40 cycles at 94°C for 15 seconds and 60°C for 60 seconds.
Analysis of qPCR data was performed using the ΔΔCq method, normalized to the
geometric mean of GAPDH and CASQ2 Cq values and corrected for primer
efficiency as described previously (Pfaffl 2001).
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8.8 RNA-Seq
Thanks to the generous collaboration from Drs. Jonathan and Christine
Seidman and work done by Joshua Gorham from Harvard Medical School’s
Department of Genetics, RNA-Seq analysis was able to be performed for this
study. Analysis and sequencing of the transcriptome of WT and Het mice
following sham and TAC surgery was performed as described previously by the
Seidman laboratory (Christodoulou, Gorham et al. 2011). Briefly, RNA was
isolated from three hearts per group using the same isolation method as
described for qPCR analysis, and were used to make cDNA samples using the
same reverse transcriptase as noted above. The three samples from each group
were pooled prior to sequencing and used to create a cDNA library for
sequencing. These steps were performed by me at Loyola, and samples were
shipped to the Seidman lab for further processing and sequencing. For details of
the 5’-RNA-Seq procedure see (Christodoulou, Gorham et al. 2011). Transcript
reads were matched to their corresponding genes and a list was compiled of
30,000+ unique identified RNA species. This list was processed by excluding all
genes that were not over 1.5 fold up-regulated or 0.6 fold down-regulated
compared to specific controls. All transcripts reported that did not pass the
Benjamini-Hochberg false discovery rate test with a p value <0.001 were
considered non-significant. Gene array images were made in collaboration with
Loyola’s Bioinformatics department, with thanks to Dr. Michael Zilliox for his time
and suggestions with data analysis. Pathway analysis was performed using
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NCBI’s DAVID Bioinformatics Tool (http://david.abcc.ncifcrf.gov/).

8.9 Rat Ventricular Cardiomyocyte Isolation
Adult rat cardiomyocytes were isolated by excising the heart followed by
retrograde perfusion on a modified Langendorff apparatus. All cardiomyocyte
isolations for this work were performed by Jollyn Tyryfter in the Department of
Cell and Molecular Physiology at Loyola University. Heart digestion procedure
used a perfusion buffer (120.4mM NaCL, 14.7mM KCl, 0.6mM KH2PO4, 0.6mM
Na2HPO4, 1.2mM MgSO4, 10mM Na-HEPES, 4.6mM NaHCO3, 30mM Taurine,
10mM BDM, 5.5mM Glucose) for five minutes to stabilize the heart and wash out
all red blood cells. Isolation of the cardiomyocytes was performed using 100mg
bovine serum albumin (Sigma A6003-25G), 100mg collagenase type 2
(Worthington 41B12520), and 10mg Protease (Sigma P5147) per 100mL
perfusion buffer. This was perfused into the rat heart for two minutes, following
recirculation for 20-25 minutes. The heart was then triturated and minced
followed by filtration through a 200µm screen. Cells were pelleted by gravity or a
500 rpm centrifugation for 1 minute. Pellet was re-suspended in a 1:1 BSA
solution and Perfusion buffer. Cells were brought back up to calcium by slow
addition of 200µl of 1mM Ca2+ (3x), 10mM Ca2+ (3x), and 100mM Ca2+ (2x) with
five minute pauses between each addition (O'Connell, Rodrigo et al. 2007).

8.10 MYBPC3 Knock-down
In order to knock-down cMyBP-C in cultured rat cardiomyocytes, an
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adenovirus was created by Jody Martin, PhD, Department of Cell and Molecular
Physiology at Loyola, containing a sequence taken from work published by the
Robbins lab which had previously been used to knock-down MYBPC3
expression in neonatal cardiomyocytes using a construct with the sequence 5’GCA UGU UCU GCA AGC AGG GAG UAU U-3’ (Bhuiyan, Gulick et al. 2012).
This virus was administered to cardiomyocytes followed by 48 hours of culturing
before protein and mRNA was isolated and evaluated as mentioned previously.

8.11 Statistical Analysis
All data are represented as the mean ± standard error of the mean (SEM).
Statistical analysis was performed using Graph Pad Prism (version 6.0). Baseline
data were analyzed using one-way ANOVA with a Bonferroni post-hoc test. For
force-pCa data at two sarcomere lengths, two-way ANOVA was performed,
followed by a Bonferroni post-hoc test. For comparison of 4 and 12 week forcepCa parameters, two-way ANOVA was performed on the changed values
between each time point to compared groups to each other, and a t-test was
used to compare how single groups changed between time points. Experiments
using the TAC model used a two-way ANOVA with a Bonferroni post-hoc test.
Diastolic

echocardiography

parameters

under

baseline

conditions

were

compared using an unpaired t-test. Statistical significance was defined as
P<0.05. For RNA-Seq data analysis, significant fold changes were set a priori as
1.5 fold increase and 0.6 fold decrease. The Benjamini-Hochberg false-discovery
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rate test (Benjamini and Hochberg 1995) was used to evaluate significance in the
relative abundance of a particular gene, with the threshold for significance set at
p ≤ 0.001.
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